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Abstract 
Aspartame (Nutrasweet ®, APM) is a widely used artificial sweetener 
synthesised from aspartate and phenylalanine, both of which are freely available in 
the normal diet but known to exert toxic and teratogenic effects when consumed in large 
quantities. While APM's protagonists claim that it is the most thoroughly researched 
food additive ever, there have been only a handfull of studies on it's behavioural 
effects. This study examined the behavioural teratogenic effects of APM in the 
offspring of rats which were exposed throughout pregnancy to solutions containing 
0.05% or 0.10% APM or a buffered control solution. The animals were tested in the 
Hughes exploration box and the 12-arm radial maze using six arms baited at the 
beginning of each trial and lowering guillotine doors each time the rat returned to the 
centre of the maze to prevent the rats from adopting response strategies. In the Hughes 
exploration box, control and APM animals showed a preference for novelty. There 
were no difference between groups on measures of exploration and ambulation. In 
learning the radial arm maze task, there were no differences in the number of errors 
made by the groups and all animals learned the task to a high degree of proficiency. 
However, during the first half of the 40 sessions and relative to controls, the rats 
prenatally exposed to the 0.10% APM solution took significantly less mean time to 
enter the arms of the maze for the first six arm entries; the time taken by the 0.05% 
APM group generally fell between that of the control and 0.10% APM group. These 
results suggest that APM may have a dose-dependent effect on the time taken by rats 
to enter an arm in the radial arm maze. The validity of these results is limited by 
some methodological considerations, such as the relatively low genetic diversity of 
the groups, and this study is in need of replication. Despite these caveats, this study 
is significant as it is the only behavioural teratology study with APM to use an 
adequate cross-fostering procedure, a low dose of APM and report a dose-dependent 
behavioural effect. The discussion offers suggestions for future research that could 




The present study examined the behavioural toxicology and behavioural 
teratology of aspartame (Nutrasweet®), the latest substance to be widely used as a 
sweet alternative to the large quantities of sugar consumed by in the western diet. 
Aspartame has about the same calorific value as sugar (about 4 Kcal/ g) and a 
perceived sweetness of between 160 and 200 times the sweetness of sugar. This intense 
sweetness means that only small quantities, offering few calories, are needed to 
sweeten food. While sugar may supply as much as 17 percent (Pardridge, 1986) to 25 
percent (Roak-Foltz and Leveille, 1984) of our total daily calories, it is held 
responsible for causing obesity, dental caries (Bowen, 1984) and exacerbating diabetic 
conditions (Porikos and Van Hallie, 1984). Aspartame is not the first artificial 
sweetener to be widely used, but it is hoped that it is safer than previous sugar 
substitutes such as saccharin and cyclamate. Saccharin has been used as a sweetener 
since 1907 but in 1977 it was almost withdrawn from the American market after it was 
shown to cause cancer in laboratory animals (Gossel, 1984). Consumer protests lead to 
an American Congressional act which prevented the American Food and Drug 
Administration from banning saccharin. Saccharin is still used widely in foods, 
despite it's metallic aftertaste. Cyclamate was a popular sweetener in the 1960s but it 
was withdrawn from the American market in 1970 after it was shown to be 
carcinogenic (Gossel, 1984). 
Aspartame (L-aspartyl-L-phenylalanine methyl ester; APM) is a synthetic di-
peptide composed of the amino acids aspartic acid (aspartate, ASP) and 
phenylalanine (PHE) in a methyl ester. When ingested, APM is hydrolysed in the 
intestine to aspartylphenylalanine and methanol. The aspartylphenylalanine 
peptide is hydrolysed to ASP and PHE, mostly in the intestine but also in the 
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intestinal mucosa and in red blood cells (Tobey and Heizer, 1986; Opperman, 1984). 
Aspartame has been found to be metabolized in the same way in all mammalian 
species studied (Ranney, Opperman, Muldoon and McMahon, 1976). The catabolism of 
APM produces 40 percent ASP, 50 percent PHE and 10 percent methanol. 
All three APM catabolites are found in large quantities in any normal healthy 
diet. Large amounts of ASP and PHE are found in dietary proteins, including those in 
human milk (Baker, 1984). Aspartate is also available in some foods as a free amino 
acid. There is more methanol in fresh fruit juice than in an equal volume of APM 
sweetened beverage. Aspartate is similar to glutamate (glutamic acid, GLU), which 
is also found in a range of foods. Both ASP and GLU are known chemically as 
dicarboxylic amino acids and both are involved in a range of essential metabolic 
processes in the body, including the Krebs (energy metabolism) cycle and the urea 
(nitrogen) cycle (Stegink, 1984a). Glutamate is widely used as a flavour enhancing 
food additive in the form of monosodium glutamate. Throughout this study, ASP and 
GLU will be considered together. 
APM is currently used in New Zealand as a 'low calorie' sweetener in 'diet' soft-
drinks, as a free flowing and tablet sweetener (Equal®) and in 'diet' chewing gum. In 
1984, the New Zealand Department of Health approved APM for use as a food 
additive. This decision was based on the, approval of APM for use in foods by the 
United States Food and Drug Administration (FDA) in 1981 (Hayes, 1981) and 1983 
(FDA, 1983)1, In America, APM is permitted as a food additive in a wide range of dry 
foods and beverages (Maher, 1986). Since APM was introduced in America, 
consumption has risen exponentially to 8000 tons in 1986 (Wurtman, 1987) with over 20 
1 Personal communication from Dr. J. Fraser, Chief Scientist, Department of 
Health, Wellington, New Zealand; and see Parker (1988). 
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billion cans of APM sweetened soft drink being consumed by over 100 million Americans 
each year (Metzenbaum, 1987). 
1.1. American Approval of Aspartame 
The FDA took over eight years to assess the safety of using APM as an intentional 
food additive. The FDA considered over 100 studies relating to APM safety, including 
clinical studies on humans and toxicological testing on animals, and the FDA produced 
a series of controversial regulatory decisions (Hattan, Henry and Montgomery, 1983). 
Aspartame was initially approved in America in 1974. Soon after, the FDA 
requested the voluntary postponement of marketing and then withdrew the 
authorization. Amongst allegations of fraud and while considering legal action (see 
Olney, 1987), the validity of some of the research data submitted by the petitioner 
(G.D. Searle and Co.) was subjected to independent validation. Formal objections to 
the approval led to the establishment of a Public Board of Inquiry to examine APM's 
safety. The Board reported that the evidence for the safety of APM was inconclusive 
and that it should not be approved for marketing. However the American Bureau of 
Foods and the newly appointed Commissioner of the FDA, Arthur Hayes, did not 
agree. They concluded with " ... reasonable certainty ... " that APM was safe and it was 
approved for market release (Hayes, 1981). Hayes commented that he was " ... not 
prepared to say that there was no risk ... but ... it had been demonstrated that there 
was not a significant risk. .. " (Smith, 1981). 
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1.2. Reported Problems with Aspartame 
APM is composed of natural food agents and has been claimed to be the most 
thoroughly studied of all food additives (e.g., Gossel, 1984; Stegink and Filer, 1984). 
However, by the end of 1987 over 4000 consumer complaints had been made to the FDA 
relating to APM use (Metzenbaum, 1987). In 1984 the American Centre for Disease 
Control (see Maher,1986; Pardridge, 1986) published an investigation of 517 consumer 
complaints relating to APM use. The complaints were primarily related to either the 
nervous system (mood changes, insomnia, seizures, menstrual irregularities) or the 
gastro-intestinal system (abdominal pain, nausea, diarrhea). APM ingestion has also 
been associated with dermatological complaints (Kulczycki, 1986; Novick, 1985) and 
panic attacks (Drake, 1986). 
Roberts (1987)2 studied 551 people who had had "bizarre" and "bothersome" 
reactions to APM. Almost half complained of severe headaches, about one third 
suffered from severe dizziness and eleven lost sight in one or both eyes. Others had 
seizures and memory problems. His report to the 154th annual meeting of the 
American Association for the Advancement of Science suggested that APM posed "an 
imminent health hazard" and it should be investigated as soon as possible. Other 
recent calls for the re-assessment of APM's safety have come from the American 
Community Nutrition Institute (see Parker, 1988) and several expert witnesses before 
the 1987 United States Congressional Senate Committee on Labour and Human 
2 Roberts (1987) is a statement to the 1987 American Congressional Hearing on 
Nutrasweet based on a study published in two American Health Sector magazines. 
His report to the American Association for the Advancement of Science was reported 
anonymously in "New Scientist" magazine, volume 117, page 33, 1988). 
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Resources hearing on APM health and safety concerns (e.g., Olney, 1987; Elsas, 1987; 
Wurtman, 1987). 
1.3. Potential Problems with Aspartame 
Most of the early debate over the safety of APM resulted from a study submitted 
by the petitioner (G.D. Searle) which suggested that APM may cause brain cancer in 
rats. While this issue has not been resolved to the satisfaction of some (e.g. Olney, 
1987), it is beyond the scope of the present study and will not be considered further. 
The other main issue considered during the regulatory process was whether " ... the 
ingestion of aspartame, alone or together with glutamate, poses a risk of contributing 
to mental retardation, brain damage , or undesirable effects on the neuroendocrine 
system ... " (Hattan et al., 1983, p. 42). This concern was related to the known adverse 
effects of ASP and PHE ingestion under certain conditions and it is these issues that are 
the main focus of the present study. Although methanol, the other product of APM 
metabolism, is known to be toxic, it is widely assumed that there is no reason to suspect 
that the low quantities of methanol released by APM metabolism will be toxic (see 
Pardridge, 1986). 
The remainder of this section examines the risks associated with the ingestion of 
APM within the context of the known adverse effects of it's two principal components 
and metabolites, namely PHE and ASP. Also, a short section will examine the 
potential risks associated with the intact APM peptide. 
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1.3.1. Estimated Daily Intake of Aspartame 
As any substance can be harmful if an organism is exposed to large enough 
quantities of it, the safety of APM depends on the amount that is likely to be consumed 
as well as the amount that is likely to be harmful. The FDA determines the maximum 
acceptable intake of a food additive by dividing the minimum dose required to produce 
adverse effects in experimental animals by a safety factor. This safety factor is 
usually 100, which is an arbitrary number thought to represent a realistic safety 
margin (Hattan et al., 1983). The FDA decided that the acceptable daily intake of 
APM is 50 mg/Kg/ day. However, what is often neglected when comparing dose levels 
across species is that there is an inverse relationship between metabolic rate and body 
mass in mammals (Pardridge, 1986). Rats metabolize PHE six times faster than do 
humans, so failure to consider this difference would divide the safety factor to less 
than 17. It is unclear whether this issue was taken into account in the FDA's decision. 
If the expected daily intake of the substance is less than the acceptable daily 
intake, then the substance is considered to be safe. The American regulatory 
authorities calculated the expected daily intake of APM from market research data 
reporting the food consumed in 4000 households. They assumed that sugar was 
completely replaced by APM, where possible, and calculated a mean consumption of 
11.1 mg/Kg/day APM with a 99th percentile level of 34 mg/Kg/day. From these 
figures APM was considered safe, but it remains controversial whether these 
consumption figures are realistic. Pardridge (1987) notes that 50 mg/Kg/day of APM 
can be ingested by consuming five average servings of APM per 50 pounds of body 
weight per day. Children, with their low body weights and sweet tastes, can easily 
consume this amount. A 20 Kg child who consumes just one quart of APM sweetened soft 
drink will receive an acute dose of 25 mg/Kg (Pardridge 1986). Frey (1976) found that 
seven to twelve year old children consumed up to 77 mg/Kg/ day when given free access 
to APM containing products. Even adults have been reported to consume up to 36 
mg/Kg/day of APM with a mean daily intake of 20 mg/Kg/day (Porikos and Van 
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Hallie, 1984). These figures suggest that the FDA estimation of daily intake of APM 
is unrealistictly low and that the actual intake figure may well be in excess of the 50 
mg/Kg/ day figure which the FDA considers to be a safe level of intake. 
1.3.2. Phenylalanine 
Most of the concern about the possible harmful effects of APM has focussed on PHE. 
Phenylalanine is an essential amino acid that mammals can not synthesize and have 
to obtain from food. Phenylalanine is degraded through a variety a pathways, 
though mostly it is hydrolysed to tyrosine. Tyrosine is also an important amino acid 
and a precursor in catecholamine and melanin synthesis (Harper, 1984). Dietary PHE 
is a major source of tyrosine. The ingestion of even low doses of APM causes a sharp and 
significant increase in PHE plasma levels (Harper, 1984). Phenylalanine is 
transported readily through the blood-brain barrier (Pardridge, 1986) and the 
developed placenta concentrates PHE at a ratio of about 2:1 on the side of the fetus 
(Stegink, Pitkin and Reynolds, 1979). 
Research into the human gene linked disorder of phenylketonuria (PKU) has 
shown that high plasma PHE levels have a detrimental effect on the developing 
brain. Phenylketonuria affects about one person in 10000 - 15000 and involves a 
deficiency in the PHE hydrolysing enzymes in the liver which causes high plasma 
PHE levels. If these high PHE levels are not treated through dietary modifications, 
the young child with PKU will develop severe mental retardation during the first few 
years of life. However, the child of a woman who has non-PKU induced high PHE 
levels during pregnancy may also be born with brain damage, microcephaly, low birth 
weight, and congenital heart disease. Levy and Waisbren (1983) studied mothers 
with PKU or non-PKU hyperphenylalaninemia and their children. When controlling 
for maternal IQ differences, they found a high correlation between childrens' IQ and 
maternal PHE levels (r= -0.82) in those children who had neither PKU nor non-PKU 
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hyperphenylalaninemia. Thus, a five fold increase in maternal PHE levels was 
associated with a 10 point reduction in the childs' IQ. Maternal plasma PHE levels 
above 60 µmol/ dl PHE were likely to have noticeable adverse effects on the child and 
PHE levels greater than 110 µmol/ dl were very likely to cause mental retardation. 
This study shows that an increase in maternal PHE levels can be harmful to the fetus 
regardless of the cause of the PHE increase. From their findings, Levy and Waisbren 
suggested that maternal PHE levels may be dangerous to the fetus only once a 
threshold level is exceeded, but Pardridge (1986) maintains that there is most 
probably a linear relationship between maternal plasma PHE levels and effects on the 
fetus. The effects produced by less than 60 µmol/ dl PHE are likely to be subtle and 
less obvious than the effects of higher maternal PHE levels and these subtle effects 
may easily go un-noticed. 
Animal models of PKU have been developed using behavioural measures of 
learning as measures of cognitive impairment (see Vorhees, Butcher and Berry, 1981). 
Early animal models of PKU showed that administration of PHE could impair 
discrimination learning (Schalock and Klopfer, 1967;), avoidance learning and operant 
learning (Chamove and Harlow, 1973; Hess, Paulsen, Muller and Carlton, 1966) in rats 
and monkeys. Current animal models of PKU, which co-administer PHE and an 
inhibitor of PHE and tyrosine metabolism, report similar impairments (Vorhees et al., 
1981). 
Elevated PHE levels have been found to cause changes even in human adults. A 
three-fold increase in the normal PHE levels of 3 to 5 µmol/ dl has been shown to result 
in quantitative changes in EEG patterns and a six-fold increase has been shown to 
induce a 10 percent change in performance on a choice time experiment (Elsas, 1987). 
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Risks from Aspartame Released Phenylalanine 
Phenylalanine is an important part of any normal healthy diet. One litre of APM 
sweetened soft-drink contains about 400 mg of PHE which is about the same amount of 
PHE in either one egg, one ounce of cheddar cheese or six ounces of baked beans 
(Yellowlees, 1983). The ingestion of the FDA's acceptable daily intake of 50 mg/Kg 
APM can double the normal PHE plasma levels (Matalon, 1987) but the ability of PHE 
to reach the brain depends on the amount of competition from other large neutral 
amino acids for transport through the blood-brain barrier in a common carrier system. 
The large neutral amino acids found in dietary proteins can compete with normal 
dietary PHE for blood-brain barrier transport to the extent that brain PHE levels may 
decrease follow protein intake. But the PHE released from APM is readily able to 
enter the brain as often the APM released PHE is not accompanied by competing large 
neutral amino acids. Thus, brain changes in PHE from APM ingestion can be in the 
opposite direction from the changes which result from the ingestion of the above 
mentioned foods (Wurtman and Maher, 1984; Wurtman, 1983). Rather than being 
biologically innocuous, Maher (1986) has claimed that APM is the food most "capable 
of selectively enhancing brain PHE levels ... ever consumed". 
The competition between neutral amino acids for blood-brain barrier transport 
means that PHE can exert an indirect influence on the neurochemistry of the brain 
through changing the availability of other neutral amino acids which are 
neurotransmitter precursors (Pardridge, 1986; Fernstrom and Wurtman, 1972). 
Wurtman (1983) notes that when APM is consumed with carbohydrates and without 
protein, the rise in brain PHE levels can be double that when the carbohydrate is not 
consumed. Also, the normal changes in brain tryptophan levels that follow 
carbohydrate ingestion can be disrupted. Tyrosine and tryptophan are precursors in 
catecholamine and serotonin metabolism respectively. Experiments with rats have 
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found that abuse doses of APM and doses as low as 200 mg/Kg APM can increase brain 
PHE, tyrosine and catecholamine levels and block the normal increase in brain 
tryptophan and serotonin which follows carbohydrate ingestion (Yokogoshi and 
Wurtman, 1984; Wurtman, 1983; Coulombe and Sharma, 1986; Fernstrom, Fernstrom and 
Gillies, 1983). Autopsies of patients with PKU have found reduced amounts of tyrosine 
and tryptophan as well as "substantial" reductions in serotonin, dopamine and 
noradrenaline (McKean, 1972). However, the FDA (1987) considered that these 
studies into neurochemical changes following APM ingestion are inadequate as they 
did not take into account the natural variation in brain levels of monoamines and their 
precursors and they did not relate neurochemical changes to neurobehavioural effects. 
It is noteworthy that the FDA recently agreed to fund research to investigate this 
issue. 
Groups Vulnerable to the Effects of Aspartame Released 
Phenylalanine 
It is well recognized that PHE poses a health risk to certain individuals, such as 
those who have PKU. To enable these individuals to avoid consuming PHE in APM, 
the labels on products which contain APM are required to warn people who have 
phenylketonuria that the product contains PHE. While this may be adequate warning 
for PKU sufferers, who are usually aware of their condition, individuais with a 
heterozygous PKU gene are usually unaware of the fact that they have about half the 
normal PHE hydrolysing capacity. Consequently, the doses of APM that are required 
to cause two and four fold increases in plasma PHE levels in individuals with normal 
PHE hydrolysing capacity will, respectively, cause three and ten fold increases in 
plasma PHE levels in individuals with a heterozygous PKU gene (Matalon, 1987). 
Furthermore, acute plasma PHE elevations remain higher for longer in individuals 
with a heyerozygous PKU gene than in individuals with normal PHE hydrolysing 
capacity. As between two and ten percent of the population may have a heterozygous 
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PKU gene (Pardridge, 1986), a significant proportion of the population may be 
endangering their health by consuming APM without realising the risk. 
Even individuals with normal PHE levels and PHE hydrolysing capacity may be 
at risk from APM released PHE. Phenylalanine plasma concentrations need to be only 
three times normal levels to induce cognitive changes (page 7) and PHE plasma levels 
are doubled by only 50 mg/Kg/ day APM - a level of consumption which is easily 
exceeded (see Section 1.3.1). Also, as the acute ingestion of only 34 mg/Kg APM can 
cause a five fold increase in plasma PHE levels in fasting individuals (Elsas, 1987), a 
more pressing problem is that people who intentionally restrict their food intake may 
be particularly vulnerable to the effects of the APM released PHE. This is precisely 
the group of people who are attracted towards the use of a 'low calorie' sweetener. 
It is well recognized that the developing fetus is especially sensitive to the 
adverse effects of environmental and metabolic toxins (Vorhees and Butcher, 1982), 
including high maternal plasma levels of PHE (see page 7). The fetus may also be 
vulnerable to the effects of APM released PHE. Elsas (1987) claims that the combined 
effects of the placental barrier and the developing fetal blood-brain barrier may 
concentrate PHE in the fetus to as much as four to six times the concentration present in 
the maternal plasma. Hence a maternal plasma concentration of 15 µmoll dl PHE 
could lead to 90 µmol/ dl in the fetal brain, which is a high enough concentration of 
PHE to kill neural cells, at least in tissue cultures (Elsas, 1987). Also, the fetus 
metabolizes PHE less effectively than the adult so elevated PHE levels will remain 
in the fetus after the maternal PHE levels have returned to normal limits. As noted 
above (this Section), plasma PHE concentrations can reach 15 µmol/dl after consuming 
only 50 mg/Kg of APM and moderate elevations in maternal PHE levels may produce 
subtle dose dependent effects in their children. The western preoccupation with a slim 
female body shape may pose an extra hazard to the fetus by encouraging pregnant 
women to consume extra amounts of APM containing foods during pregnancy in an effort 
11 
to restrict their weight gain (Pardridge, 1986). As an insult to the developing fetus 
will have an effect which usually lasts for the lifetime of the animal, the group most 
affected by APM released PHE may be the unborn. 
1.3.3. Aspartate 
While most researchers who are concerned with the safety of APM have focussed 
their attention on the PHE moiety, Olney (see Olney, 1984, 1987; Olney, Labruyere and 
deGubareff, 1980) has consistently maintained that APM ingestion may be harmful 
through the action of it's ASP moiety. Claims that APM-released ASP may pose a 
health risk are more controversial than similar claims about PHE and therefore the 
following section will consider the relevant issues in some detail. 
Aspartate (ASP) and the structurally and functionally similar glutamate (GLU) 
are found in large quantities in any healthy diet (see Section 1). Aspartate and GLU 
are absorbed from the intestinal lumen faster when they are free amino acids than 
when they are bound in peptides (Stegink, 1984b). Dietary carbohydrates stimulate 
ASP and GLU metabolism in the intestine and reduce the amount of ASP and GLU 
absorbed into the blood. Therefore, low carbohydrate 'diet' foods enable the maximum 
absorption of APM released ASP . 
Aspartate and GLU are present in the brain in their metabolic role and as 
neurotransmitters, most probably as the transmitters released at excitatory synapses in 
the vast majority of cells in the mammalian CNS (Cotman and Monaghan, 1987; Cox 
and Bradford, 1978). Evidence for this includes (i) in vitro and in vivo demonstrations 
of Ca2+ dependent release of L-GLU and L-ASP; (ii) the identification of specific post-
synaptic excitatory amino acid receptors responsible for mediating synaptic 
transmission; and (iii) the presence of fast inactivation mechanisms. Most CNS cells 
can be assumed to have receptors for ASP and GLU, irrespective of the presence of 
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other types of receptors on the same cell (Watkins, 1978). The action of ASP and GLU 
are mediated by at least four different receptors. Three of these have been identified 
using GLU analogues which have selective agonist action. These GLU-agonists are N-
methly-D-aspartate (NMDA), kainate (KA) and quisqualate (QA). L-GLU displays 
a high affinity for the binding sites for each of these three agonists. The existence of 
the fourth receptor has been identified by a GLU analogue antagonist but a receptor 
has not yet been clearly identified (Cotman and Monaghan, 1987). 
Among their many other roles in the brain, ASP and GLU are probably involved in 
the neurobiology of memory. Current neurobiological theories of memory emphasize a 
unique form of synaptic transmission which results in a long-lasting enhancement of 
synaptic efficiency (McNaughton, 1983). This process has been named long term 
potentiation (LTP). Most research on LTP has focussed on the hippocampal system 
(Lee, 1983), believed by most researchers to play an important role in memory (but see 
Jarrard, 1986). Aspartate and GLU appear to mediate transmission in some of the 
hippocampal pathways in which LTP has been experimentally induced (Wieraszko, 
1983). Also, APV-5, a NMDA antagonist, has been found to block LTP formation in 
rats, in vivo and in vitro, impair spatial learning in the Morris water maze but not 
impair the the learning of a simple discrimination task in the Morris pool (Anderson, 
Baudry and Morris, 1985; Morris, Anderson, Lynch and Baudry, 1986). This finding 
supports the role of excitatory pathways in hippocampal LTP formation, as spatial 
memory, but not non-spatial memory, is believed to depend heavily on the workings of 
the hippocampus (Pribram, 1986). 
Excitotoxicity of Aspartate 
Despite these important metabolic and neurophysiological functions, high 
systemic doses of prenatally or postnatally administered ASP and GLU can destroy 
neurons in the circumventricular (CV) regions of the brain and the cingulate cortex of 
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neonatal mice (Olney, 1978). The most severely affected area is the arcuate nucleus of 
the hypothalamus which is involved in regulating neuroendocrine functions. High 
doses of ASP and GLU, by any route of administration, result in a well described 
syndrome of obese, stunted linear growth, sterility and some behavioural disturbances. 
Reported behavioural changes include delays in developmentally appropriate 
behaviours (Butcher and Vorhees, 1984), conflicting reports of increased and decreased 
activity levels (see Dawson and Lorden, 1981) and impaired performance on some 
learning tasks (see Section 1.5). Aspartate is as effective as GLU in inducing this 
syndrome (Pizzi, Tabor and Barnhart, 1978). 
Olney (1978) demonstrated a correlation between the neuro-excitatory potential 
and the neurotoxic effects of a large range of GLU analogues. Specific antagonists of 
GLU or its analogues prevent these substances from exerting a neurotoxic effect (Olney, 
1984). Neurotoxicity occurs when the excitatory action of these amino acids is not 
controlled. Normally, the ASP and GLU used in neurotransmission is synthesized 
within the neuron, released into the synapse in very small quantities and removed 
from the synapse by an extremely effective uptake system (Stone,. Connick, Hastings 
and English, 1987). But if ASP and GLU are present outside the nerve cell for 
prolonged periods, it is claimed that they will " ... literally excite the neuron to 
death" (Olney, 1987). As neurotoxicity results from the excitatory effects of these 
amino acids, they have become widely know as "excitotoxins". Different excitotoxins 
may exert their effects in slightly different ways (Coyle,1987; Schwarcz, Foster, 
French, Whetsell and Kohler, 1984), but it is generally believed that excitotoxicity 
can be either an immediate or a delayed event following the exposure of a neuron to an 
excitotoxin (Collins, 1986). Immediate excitotoxicity is caused when sustained 
depolarization of the neuron holds open membrane channels and allows an increase in 
ionic concentrations in the post-synaptic dendrites and soma. By osmosis, water also 
moves into the cell and causes an increase in tension on the cell membrane and, 
eventually, cell death. Sodium, calcium and chloride ions may be involved in the 
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intracellular increase in osmolarity (Collins, 1986, 1987; Schwarcz and Shoulson, 1987) 
but, in at least some brain cells, an influx of extracellular chloride ions is especially 
important (Rothman, 1985). Delayed excitotoxicity appears to rely more on the 
indirect action of calcium ions, but the exact mechanism of this process is not known 
(Collins, 1987). 
Systemically administered excitatory amino acids are unable to reach most regions 
of the brain because of an efficient efflux carrier system for acidic amino acids in the 
blood-brain barrier (Pardridge, 1986). However, large doses of ASP and GLU have 
been shown to increase tissue concentrations in the CV and cingulate regions of the 
brain (Price, Olney, Lowry and Buchsbaum, 1981) as these regions are not protected by 
the blood-brain barrier. Other, extrahypothalamic regions of the brain are 
apparently unaffected, even by repeated high dose administrations of excitotoxins 
(Coyle, 1987). Systemically induced excitotoxicity is generally noted only when 
excitotoxins are administered at high doses so that plasma levels of GLU and/or ASP 
are elevated to about 60 - 100 µmol/ dl in infant mice, which is about five to ten times 
normal levels (Applebaum, Daabees, Stegink and Kinkelstein, 1984; Stegink, 1984). In 
ten day old mice, the lowest effective experimental dose needed to produce these 
plasma levels and induce excitotoxicity is 0.5 g/kg administered orally and 0.35 g/Kg 
administered subcutaneously (Cotman and Monaghan, 1987). Adult animals require 
four times this dose to produce comparable neurotoxic effects (Olney, 1984), probably 
because of age related changes in absorption, metabolism and the rate of extra-cellular 
uptake by neurons and glial cells (Coyle, 1987). 
The excitotoxic action of ASP, GLU and particularly their analogues is so effective 
at killing neurons that excitotoxins have been used extensively as research tools. 
Lesions induced by systemic administration have been used to investigate 
neurotransmitters, neural pathways and neurohormone function within the 
hypothalamus (Coyle, 1987). Regional injection of excitotoxins into the brain provide 
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a unique method of neurobiological investigation as excitotoxins damage only the 
dendrites and somata of neurons while sparing axons that pass through the region 
(McGreer, Olney and McGreer, 1978). This technique avoids the problem encountered 
with less selective lesion methods where the resulting behavioural disturbances may 
be due to damage caused by the lesion of axons passing through the area (Jarrard, 
1986). 
Of clinical interest, excitotoxic mechanisms are believed to be involved in a range 
of neurodegenerative disorders which involve memory impairment and display an 
overlapping pattern of selective neural degeneration. The neural degeneration 
associated with seizures, hypoxia, hypogykemia, stokes and cardiac arrest is 
believed to caused by a sudden release of ASP and GLU from neurons while uptake 
mechanisms are temporarily inoperative (Collins, 1987; Colye, 1987). Indeed, NMDA 
antagonists have been shown to protect brain tissue from this kind of damage 
(Schwarcz et al. , 1984). Progressive degenerative disorders believed to involve 
excitotoxic mechanisms include Huntingtons disease (Schwarcz and Shoulson, 1987) 
and Alzheimers disease (Deutsch and Morihisa, 1988). The 'leakage' in the blood-
brain barrier observed in normal elderly individuals and individuals with 
Alzheimers disease may allow excitotoxic doses of ASP and GLU to reach, and 
damage, sensitive regions of the brain. 
Neurons in the hippocampal system appear particuiarly sensitive to excitotoxic 
damage and from a range of other metabolic and toxic insults (Walsh and Chrobak, 
1987). This damage to the hippocampus is probably a major contributing factor to the 
memory disturbances which accompany some of the disorders discussed in the previous 
paragraph (but not Huntingtons disease). Although the blood-brain barrier protects 
the hippocampal formation from increased levels of excitatory amino acids, some 
hippocampal neurons are particularly vulnerable to intraventricular injections of KA 
(Nadler, Perry and Cotman, 1978). Also, the cingulate cortex is unprotected by the 
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blood-brain barrier and is a target for efferent projections arising from the CAl and 
CA3 cell fields in the hippocampus (see Jarrard, 1986). As excitotoxic lesions to 
afferent and efferent projections of the hippocampus impair memory function in rats 
(Jarrard, 1986), excitotoxic amino acids may be able to exert an indirect effect on the 
hippocampal system by acting on the cingulate cortex. 
Risks from Aspartame Released Aspartate 
It is unclear whether humans are likely to be affected by the excitotoxic action of 
ASP and GLU. Olney and colleagues have reported neuronal necrosis in infant non-
human primates given large doses of GLU (Olney and Sharp, 1969; see Olney, 1984) but 
four other research groups were unable to detect such lesions, even when using large 
doses of APM and MSG which produced gross elevations in plasma ASP and GLU 
levels (see Stegink, 1984a). But whether or not APM-induced excitotoxicity is a danger 
to humans, sub-toxic doses of ASP and GLU may exert other more subtle effects. Olney 
and colleagues (see Olney, 1984; Olney and Price, 1978) reported that sub-cutaneous 
doses of 100 mg/Kg GLU given to infant mice induced neuroendocrine changes which 
were probably secondary to excitatory stimulation of neurons in CV regions which 
regulate pituitary function. Sub toxic doses of NMDA have produced similar findings 
in both rats and monkeys (Wilson and Knobil, 1982). Olney has suggested that 
neurohonnonal changes resulting from sub-toxic doses of excitatory amino acids may 
lead to the slow development of "silent lesions" (Olney, 1984). Efforts to replicate 
these neurohormonal finding have been somewhat mixed and some authors have 
attributed Olney's findings to circadian variations in hormonal levels (e.g., 
Sturtevant, 1984). Nevertheless, some researchers (e.g., Dawson, 1987) remain 
concerned about possible APM induced disturbances on the neuroendocrine system, 
especially in the young. 
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While the rate and efficiency of the gastrointestinal absorption of APM released 
ASP and PHE have not been well studied, Olney (1984) notes that the literature on 
MSG shows that humans absorb GLU probably ASP much more efficiently than other 
species. However, Stegink (1984b) reported that plasma ASP levels in humans did not 
rise significantly following 34 mg/Kg APM with or without accompanying 
carbohydrate. Pardridge (1986) used data from MSG studies to estimate that plasma 
ASP levels following an acute dose of 50 to 100 mg/Kg APM, without carbohydrates, 
would rise modestly to about 10 µmol/ di. However, Olney notes that the literature 
relating to GLU absorption suggests that there is a large variation in the rate at 
which humans absorb GLU and the data reviewed by Olney shows that plasma levels 
of GLU increase at a hyperbolic rate with GLU ingestion. Hence significant increases 
in ASP levels may be achieved by heavy consumption of APM in at least some 
individuals. 
Groups Vulnerable to the Effect of Aspartame Released Aspartate 
The discussion in the previous paragraphs revealed that it is unclear whether 
systemically administered excitatory amino acids can exert excitotoxic or 
neurohormonal effects of humans or whether APM released ASP can significantly 
increase plasma ASP levels. Also, the blood brain barrier will isolate the brain from 
any changes in plasma ASP level (see page 15). However, if APM released ASP can 
enter the body, those individuals with a degenerating or incomplete blood-brain 
barrier may be especially at risk. Indeed, the 'leakage' in the blood brain barrier 
noted in elderly people and individuals with Alzheimers disease has been suggested 
as a way that excitatory amino acids may enter the brain and exert a excitotoxic 
neurodegenerative effect (Deutsch and Morihisa, 1988). APM related increases in 
plasma ASP may be an extra hazard for this group. Another group at risk from APM 
released ASP may be the unborn and neonates. The blood-brain barrier does not become 
functionally mature until shortly after birth (Price et al. , 1981) and hence the 
18 
unprotected prenatal brain could be exposed to the adverse effects of systemically 
administered excitotoxins. However, to reach the fetus, any substance must first cross 
the placental barrier. Unlike most amino acids, ASP and GLU are not concentrated in 
the fetus by the placenta. Instead, fetal plasma levels have been experimentally 
elevated only when maternal plasma concentrations are 70 times normal levels of GLU 
(Carattini, 1979) and over 100 times normal levels of ASP (Stegink et al., 1979). 
Studies which have investigated the placental transfer of ASP and GLU have 
done so during the late stages of gestation, or else they have not stated the stage of 
gestation at which they were performed. While investigation of only these late 
stages may be methodologically easier, it overlooks the rapid development of the 
placenta which occurs mainly during the first third of mammalian gestation. The 
initial structure of the yolk sac placenta gives rise to the allantois and the chorion 
which eventually fuse to form the mature, chorioallantoic placenta (Mossman, 1987). 
The transport properties of these changing placental structures varies with their 
development (Ullberg, Dencker and Danielsson, 1982) but not enough is known about 
these changes to accurately predict the transport properties at one stage of 
development from knowledge of the transport properties at another stage. 
The chorioallantoic placenta is developed in humans by the third month of 
gestation (Thomas, 1985) and in rats by the twelfth day (Juchau, 1982). While the 
mature placenta appears to be an effective barrier to high maternal plasma levels of 
ASP, the developing placenta may not be so effective. The nervous system, which is 
the first organ to develop in the embryo (Patel, 1987), is especially sensitive to the 
effects of teratogenic agents during the period of organogenesis (Vorhees, 1986b). 
Organogenesis occurs from days 13 to 56 in humans (Thomas, 1985) and days 6 to 16 in 
rats (Vorhees, 1986). Thus, there is considerable overlap between the periods when 
the embryo is most sensitive to teratogenic insult and the placenta is least developed. 
If ASP can enter the fetus prior the the functional maturity of the placenta, it may 
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exert an effect on the developing nervous system through it's excitotoxic action or 
through it's normal neuroactive properties. The unusual presence of neuroactive 
substances, including unusual concentrations of neurotransmitters, can disturb the 
development of the nervous system by changing the balance and timing of the 
organization of developing neuronal interconnections (Patel, 1987). 
To conclude this discussion of the risks associated with APM released ASP, it must 
be emphasised that the hypothesised danger rests heavily on a number of 
uncertainties which exist in the literature. For instance, it is not clear that the ASP 
released from APM can significantly alter plasma ASP levels, cross the immature 
placental barrier or exert a teratogenic effect. However, it is clear that the 
widespread use of APM warrants the thorough invesigation of all these possibilities. 
1.3.4. Aspartame and Related Peptides 
While the metabolites of APM, namely ASP, PHE and methanol, are present in 
the normal diet, the intact APM peptide and other peptides produced by APM's 
metabolism and degradation are synthetic substances which have no natural 
occurrence or function. These synthetic substances may be potentially harmful. 
Aspartylphenylalanine is a peptide released during the intestinal hydrolysis of 
APM. There are a number of other peptides produced by the normal slow degradation 
of APM and the rate of this degradation can be greatly increased by changes in pH and 
temperature (Pardridge, 1986). Little is known about most of these decomposition 
products (Bada, 1987). One long term feeding study found no toxic effects when the 
diketopiperazine derivative of APM was added to the normal diet of rats (Ishii, 
Koshimizu, Usami and Fujimoto, 1981) but the crystals of the substance added to the 
diet were sufficiently coarse that the rats may have avoided eating them (see Olney, 
1987). 
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Intestinal metabolism protects the body from the potentially toxic effects of large 
quantities of peptides in the blood (Mathews, 1984) and the fast intestinal hydrolysis 
is presumed to prevent APM from entering the blood (e.g., Oppermann, 1984). 
However, some of the known side effects of APM ingestion, such as skin reactions, are 
unlikely to be caused by APM's natural metabolites and therefore they are probably 
caused by an APM or related peptide (Pardridge, 1986). This suggests that APM 
peptides can enter the blood of at least some, if not all, people. 
The presence of synthetic peptides in the maternal system may be an extra hazard 
for the fetus. A major role of the placenta is to prevent unwanted substances from 
entering the fetus but the placenta may not be very effective at regulating the 
transport of synthetic substances which have not been present in the environment 
during the placenta's evolution (Ullberg, Dencker and Danielson, 1982). The lack of 
effective regulation of the placental transfer of synthetic substances may be why so 
many drugs, pesticides and industrial chemicals can exert teratogenic effects on the 
fetus. 
1.4. Behavioural Toxicology of Aspartame 
The previous sections have identified ways that APM may be harmful to the 
organism. While most investigations of the toxicity of an agent focus on the 
pharmacology of it's action, toxic agents also have behavioural effects. It is this 
behavioural toxicology that is of most interest and most relevance to psychology. 
While it it has been claimed that APM is the most thoroughly studied food additive 
ever (e.g., Stegink and Filer, 1984; Gossel, 1984), there appear to be surprisingly few 
studies on the behavioural effects of APM. In an effort to locate behavioural studies, 
the present author carried out an on-line computer search of psychology and medical 
databases, searched sources cited in a book chapter on the behavioural effects of APM 
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(Butcher and Vorhees, 1984), searched for APM related titles listed in "Current 
Contents", and consulted a list of all APM related literature published in the world 
between 1981 and late 1987 (published in the 1987 American Congressional Hearing on 
Nutrasweet). While some behavioural studies were probably submitted to the FDA as 
part of the petition for the approval of APM, these are not freely available for 
review. Excluding studies which examined only activity measures associated with 
the excitotoxic syndrome (Section 1.3.3), only five studies were found which examined 
the behavioural toxicology of APM. This section will review these studies. 
Potts, Bloss and Nutting (1980) added to the normal diet of weanling rats 0, 5.5 or 
11 g/Kg APM, or PHE doses equivalent to the amount of PHE consumed in the APM 
conditions. The rats were fed this diet for 90 days. Males, but not females, in the high 
PHE and APM groups made significantly fewer avoidance responses in a shuttle-box 
avoidance task. The high PHE male group also received significantly more shocks 
during the second half of testing on a Sidman (non-discriminated) avoidance task, but 
not during the test overall. There were no significant dose dependent differences 
between any groups on cage activity measures. The authors attributed the observed 
effects of APM to it's PHE constituent. 
Reynolds, Bauman, Stegink, Filer and Naidu (1984) fed five groups of four infant 
stumptail monkeys infant formula diets containing 0, 1, 2, or 3 g/Kg APM or 1.65 g/Kg 
PHE for 270 days. They found no difference the groups on a range of developmental 
measures and the only distinguishable difference was elevated water intake in the 3 
g/Kg APM and 1.5 g/Kg PHE groups. Suomi (1984) tested the same animals on a 
standardized primate learning test battery and reported no differences in performance 
between the experimental groups, control group or norms gathered from previous 
studies that used the same test battery. While large group sizes are not feasible in 
primate studies differences must be large to achieve statistical significance, the 
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authors do not mention any indication of groups differences but neither do they report 
the actual data. 
Nomura (1985) administered a single acute dose of 250 mg/Kg APM by stomach 
tube to a group of rats that had previously been trained on (i) a brightness 
discrimination task with a multiple variable interval and extinction schedule and (ii) 
a fixed ratio (50) scehdule. Relative to controls, the APM group displayed no 
difference in patterns of responding on these schedules. 
Gershbein, Dachman, Gershbein and Kambhampati (1987) examined exploratory 
behaviour using the hole-board test with rats administered low doses of APM by 
drinker. They found that males, but not females, administered 0.0625% by drinker for 
42 days from 46 days of age made significantly fewer hole pokes in later minutes of the 
trials than control rats. However they were unable to replicate this finding. In a 
separate experiment they found that weanling rats given 0.625% APM for 19 days and 
then 0.0625% APM for 24 days made significantly more hole pokes than control rats or 
rats which received 0.0625% APM throughout the 45 day period. However, these 
workers were unable to observe any differences between rats given the spit 
0.625 /0.0625% APM dose regime from 47 days of age. The weight quantity of APM 
consumed by the rats was not reported in this study. Gershbein et al. did not try to 
interpret these conflicting findings. 
Pinto and Maher (1988) found that pretreating rats by oral intubation with 1 to 2 
g/Kg APM significantly increased the sensitivity of mice to chemically induced 
seizures and decreased the time between when the pro-convulsant agent was 
administered and when seizure was first observed. They also found that equimolar 
amounts of PHE, but not ASP or methanol, induced a similar sensitivity to seizure and 
the co-administration of APM and valine, a large neutral amino acid, did not increase 
seizures. They concluded that the sensitivity to seizures was mediated by PHE, 
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possibly secondary to a suppression of brain catecholamine synthesis caused by PHE 
lowering the brain uptake of tyrosine (see Section 1.3.2). 
Together, these five studies tentatively suggest that APM may exert an adverse 
effect on behaviour at high doses and possibly at low doses. Both the Potts et al. 
(1980} study and the Gershbein et al. (1987) study report an unclear pattern of sex 
differences and significant findings on only the second half of some of the tests. These 
few studies have examined different aspects of behaviour and, as a result, no 
behaviours have been thoroughly studied. Clearly, the behavioural toxicology of 
APM has not been adequately investigated. 
1.5. Behavioural Teratology of Aspartame 
While toxicology focuses on the effects of postnatal exposure to an agent, 
teratology is primarily concerned with the morphological and functional effects of 
prenatal experiences. This pre/post-natal dichotomy overlooks the continuing process 
of development and the different developmental stage of different species at birth. 
Instead, it places emphasis on the time of dramatic change in the nature of the 
offspring's reliance on the mother (Vorhees, 1986a). Teratology originally developed 
from toxicology with a particular concern for the study of congenital birth deformities, 
but it has expanded, or perhaps a sub-specialty has emerged, with an emphasis on the 
behavioural abnormalities which arise from the prenatal exposure to a teratogen 
(Grimm, 1987). These behavioural differences are assumed to reflect some level of 
morphological change, but the behavioural changes are considered to be more sensitive 
measures of teratogenicity than physical malformations as the ability of tissue to 
perform its adaptive function is considered to be a more valid measure of its integrity 
(Butcher and Vorhees, 1984). 
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After briefly mentioning the importance of behavioural studies in it's introduction, 
the fifth edition of the Catalogue of Teratogenic Agents (Shepard, 1986) considered 
APM not to be teratogenic on the basis of two studies by the same research group which 
reported no significant increases in plasma amino acid levels after APM ingestion. 
However, the evidence outlined in earlier sections suggests that the fetus whose 
mother ingests APM may in fact be at risk from the effects of PHE and/ or ASP and 
possibly from the effects of the intact APM peptide. Behavioural measures may offer 
a sensitive index of subtle effects but there have been few studies of the behavioural 
teratology of APM - the current author managed to find only two behavioural 
teratology studies with APM. These studies are reviewed below. Olney (1987) 
mentions that two teratology studies were submitted to the FDA by G.D. Searle and 
Co. but these may not have been behavioural studies, these studies are not published 
and, according to Olney, they are of dubious reliability. 
Mahalik and Gautieri (1984) administered 0, 1 or 4 g/Kg/day APM, or saline 
control solution, by stomach intubation to pregnant mice during days 15 to 18 of 
gestation. While APM had no effect of the development of three reflexes studied, 
namely negative geotaxis, surface and air righting, there was a significant dose-
dependent delay in the age at which the APM treated offspring developed a visual 
placing reflex, defined as the rat extending it's front paws to a rope placed below it. 
The authors concluded that this delay in such a basic developmental task suggested 
that prenatal exposure to high doses of APM can cause functional impairments in mice. 
However, this study did not employ a cross-fostering procedure and therefore the 
observed differences may have been due to the effects of APM on the dams. 
Brunner, Vorhees, Kinney and Butcher (1979) added 0, 2, 4 or 6 % APM or 3 % PHE 
to the normal diet of groups of male and female Sprague-Dawley rats from before 14 
days before mating. The PHE group was included to provide data to compare with any 
APM treatment effects. The dams continued this diet until their offspring were 
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weaned and the offspring continued these diets throughout their life. The dose of APM 
consumed by the 6% APM dams was about 5 g/Kg/ day throughout gestation and about 
9.5 g/Kg/day throughout lactation. Post-weaning, the 6% APM offspring consumed 
about 9 g/Kg/ day APM. The lower dose groups consumed approximately proportional 
doses of APM, with respect to their experimental dose condition (e.g., 0, 2, or 4% APM). 
The 6% APM and especially the 3% PHE groups showed a significant increase in 
offspring mortality and significantly delayed development. The 4% APM group 
showed some delays in development. When tested pre-weaning in an open field test, 
the 6% APM and 3% PHE groups showed longer initial latencies to leave the centre 
square and reduced locomotor activity. When tested post-weaning in an open field 
test, only the female 6% APM group showed an increased initial latency. 
The offspring in Brunner et al. 's (1979) study were weaned at 21 days and housed in 
individual cages at 24 days. Post weaning, all animals were tested on a running wheel 
and a rotor rod balancing test, and two learning tasks. The learning tasks were (i) an 
active avoidance task, with a wheel turn response and white noise signalling foot-
shock; and (ii) a two-chamber (light/dark) passive avoidance task, with foot-shock 
in the dark chamber on the first day. No treatment effects were observed on these 
learning tasks. However, the generality of these results is seriously compromised as 
the offspring were reared in social isolation. Compared with group-housed litter-
mates, rats reared in social isolation are well known to exhibit enduring changes in 
their performance on a variety of activity and learning tasks (e.g., Dalrymple-Alford 
and Benton, 1984; Einon, 1980). It is possible that an isolation by treatment interaction 
may have obscured any effects. 
The Brunner et al. (1979) study also examined two additional groups of offspring (0 
and 6 % APM) under identical conditions as above. However, at birth these offspring 
were cross-fostered to the dams of the other condition (i.e., pups of control dams were 
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given to 6% APM dams, and vice versa}. The offspring which received APM 
postnatally showed similar developmental delays as the 6% APM and 3% PHE groups 
in the main experiment, but the offspring which received APM prenatally showed no 
such impairments. From this experiment, the authors concluded that the adverse 
effects observed in the main experiment were due to exposure to APM during the 
postnatal period and, therefore, the effects are not actually teratological effects. In a 
later article, the same authors claimed the effects were probably due to the inability 
of the young animal to effectively hydrolyse PHE (Butcher and Vorhees, 1984). Their 
conclusion seems unwarranted for the following reasons: The authors (Brunner et al., 
1979} reported that in the cross-fostering experiment the APM fed dams and control 
dams were similar weights at the time of birth but APM fed dams lost weight 
throughout lactation, relative to controls. Also, at birth there was no difference 
between the weights of pups in either group, but pups that were fed by APM fed dams 
lost weight throughout lactation, relative to controls. These combined findings suggest 
that the high doses of APM affected the lactating rat. It would be more parsimonious 
to conclude that the effect on the dams may have in turn affected the pups by altering 
the standard of nutrition and/or care which they received. To determine whether any 
of the observed effects were due to prenatal or postnatal exposure to APM or maternal 
factors, both control and APM exposed offspring would need to be fostered to control 
dams. 
Despite the uncertainty over the actual origins of the effects in the Brunner et al. 
(1979) study, the authors concluded that the effects were due to the PHE moiety of 
APM. Similar explanations have been made in behavioural toxicology studies (e.g., 
Potts et al., 1980). However, at least two studies have reported altered learning 
performance and changes in activity measures following prenatal exposure to MSG. 
The functional similarity between ASP and GLU suggest that similar doses of ASP 
may exert similar effects. These two studies will be briefly reviewed. 
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Butcher and Vorhees (1984) cite an earlier study published by their group which 
found that 5.1 % MSG administered in the diet of pregnant rats produced 
developmental delays, slower (impaired) active avoidance and longer 48-hr passive 
avoidance response latencies. This increase in passive avoidance latency could be 
interpreted as increased retention and enhanced memory, but performance on passive 
avoidance tasks can be confounded by emotional factors. This study could not be found 
in the reference cited and therefore the actual MSG dose and test procedures could not 
be established. In the second study, Frieder and Grimm (1984) administered 10 
g/Kg/ day MSG in the drinking water of three female rats throughout the last two 
thirds of their pregnancy. Two untreated dams produced control condition offspring. 
(It is assumed that offspring were not cross-fostered as a cross-fostering procedure was 
not reported). There were no significant differences between the performance of the 
groups on a shuttle-box avoidance learning task or a simple successive brightness 
discrimination task (black/white runway). However, rats prenatally exposed to MSG 
made significantly more errors in the later trials of a six unit simultaneous 
discrimination learning task. The MSG rats also exhibited morphological and 
activity level changes attributable to the excitotoxic syndrome (Section 1.3.3). These 
two behavioural teratology studies with MSG support the idea that APM released 
ASP may be capable of exerting a behavioural teratogenic effect. 
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1.6. Rationale for the Present Study 
The above discussion suggests that APM may be able to exert adverse effects on an 
animal. These effects may result from both the PHE and ASP moieties of APM and 
perhaps the intact APM peptide. The prenatal animal may be most vulnerable to 
these effects. 
It was proposed above that ASP may be able to enter the maternal system and the 
embryo during the early period of gestation when the placenta has not reached a level 
of functional maturity. As ASP is a putative neurotransmitter, it may affect the 
embryo by being present in the developing nervous system at unusual concentrations 
during the initial stages of organogenisis and neural proliferation. Aspartate may 
also affect the young nervous system through its excitatory and/ or excitotoxic action. 
Aspartate is involved in the neurobiology of memory and excitatory pathways are 
involved in LTP formation in the hippocampus. As the hippocampal system is 
unusually vulnerable to excitotoxic, toxic and metabolic insults, prenatal exposure to 
low dose APM released ASP may exert a subtle behavioural teratogenic effect on the 
learning and memory ability of the animal. Also, PHE is concentrated in the prenatal 
brain and can impair learning and memory performance, most probably in linear dose-
dependent way. Therefore low doses of APM may be able to exert a behavioural 
teratogenic effect that may be detectable by examining learning and memory 
performance. The present study sought to test this hypothesis by examining the 
performance of rats, prenatally exposed to two low doses of APM, on a complex 
learning and memory task. In light of the sex differences noted in the studies by 
Brunner et al. (1979), Potts et al. (1980) and Gershbein et al. (1987), the present study 
examined both male and female offspring. 
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With respect to the teratological nature of the present study, a cross-fostering 
procedure was employed. An agent that appears to exert a behavioural teratogenic 
effect may do so indirectly by changing the rearing habits of the mother or changing 
the standard of nutrition and/ or care which she supplies to her offspring. Cross-
fostering all offspring to a control group, non-biological parent allows treatment effects 
to be determined by eliminating the possible indirect effects of the treatment on the 
dams. Vorhees (1986b) claims that cross fostering is a resource intensive procedure 
that is necessary only in the later studies of the investigation of a teratogen. He 
considers preliminary experiments, without cross-fostering procedures, must first 
establish evidence of apparent behavioural teratogenic effects. While this may be an 
acceptable strategy for extensive programmes of behavioural teratology research, it is 
not suited to the single experiment, such as the present study. It is noteworthy that 
the inadequate cross-fostering procedures employed by Vorhees and associates 
(Brunner et al., 1979, see Section 1.5) undermined the only previous behavioural 
teratology study of APM which has investigated performance on learning tasks. 
The two previous behavioural teratology studies of APM (Mahalik and Gautieri, 
1984; Brunner et al., 1979), both used high doses. Vorhees (1986) recommends that 
behavioural teratology investigations begin with large doses and only use lower doses 
once a risk has been established. However, the literature on APM demonstrates that 
high dose studies are not always followed by low dose studies (e.g., Brunner et al., 
1979) and high dose studies tell us little about the effects of doses and patterns of use 
which more analogous to human consumption. The use of a low dose of APM is 
supported by the initial findings of the Gershbein et al. (1987), that 0.0625% APM by 
drinker may affect exploratory behaviour in rats, and recent calls in the literature to 
investigate the effects of APM at doses more relevant to human patterns of 
consumption (e.g., Pardridge, 1986; Elsas, 1987; Metzenbaum, 1987). Hence, the present 
study chose to investigate the effects of prenatal exposure to low doses of APM . Two 
low doses were used to enhance the likelyhood of finding an effect. 
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The present study used a radial arm maze task as a complex learning and memory 
test and the Hughes exploration box as a measure of exploratory behaviour. There are 
many different experimental procedures used to measure learning and memory in the 
laboratory rat, but in commenting on a series of behavioural teratology studies, Grimm 
and co-workers (see Grimm, 1987) noted that behavioural deficits were not observed on 
simple avoidance tasks where as they were observed on more complex simultaneous 
discrimination learning tasks, some of which involved avoidance responses. Many of 
the studies reviewed above employed active and passive avoidance tasks to measure 
learning and these tasks have been used together as measures of hippocampal damage 
(Rodier, 1978). However, there are a number of problems with these tasks (Tadokoro, 
1987; Gerber and O'Scaughnessy, 1986). These procedures require an animal to either 
perform a particular behaviour (active) or not to perform a particular behaviour 
(passive) in order to avoid the presentation of aversive stimuli. As well as differences 
in memory, avoidance behaviour is also affected by differences in the sensitivity and 
reactivity of the animal to aversive stimuli. Hence differences on avoidance tasks 
may reflect sensory and emotional differences in the animals. Also, the behavioural 
effect noted on these tasks can be critically dependent on the actual task performed. 
For example, some patterns of hippocampal damage can decrease avoidance on a one 
way active avoidance task but increased avoidance on a two way active avoidance 
task; performance of passive avoidance tasks can be similarly mixed (Gray and 
McNaughton, 1983). 
The present study used a radial arm maze to test the learning abilities of rats 
prenatally exposed to a low dose of APM from conception. The radial arm maze 
(RAM), also known as the Olton spatial maze (Adams, 1986), is composed of a central 
platform with usually eight or more arms radiating from it like spokes of a wheel 
(Olton, 1987). A guillotine door is positioned at the entrance of each arm to so the rat 
(or mouse) can be prevented from entering that arm. There is a barrier on one side of 
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each arm near the centre of the maze which prevents the rat from jumping from one 
arm to the next without revisiting the hub. While exact test procedures differ, the rat 
is usually confined to the centre of the maze and then allowed to search the maze for 
food placed in the food wells at the end of some or all arms. The guillotine doors are 
lowered each time the rat enters an arm and then raised shortly after the rat has 
returned to the centre of the maze. This procedure ensures that the next arm which the 
rat chooses is determined by at least some amount of choice and not by the response 
habits of the animal (Olton, 1983a). 
The RAM is a well validated measure of spatial memory in the rat. The number of 
times that a rat visits or revisits an arm which contains no food is taken to be an index 
of spatial memory. The RAM is claimed to have ethological validity as it can be 
conceptualized as representing a foraging task (Olton, 1987). In the RAM, the rat is 
required to learn a list of spatial locations. List learning is also a feature of human 
cognitive tests, such as the Weschler scales, and performance on list learning tasks is 
usually impaired in humans suffering from amnesia. Impaired RAM performance is 
found in rats after experimental brain damage to the septo-hippocampal system and 
damage to these regions of the brain in humans is believed to result in selective 
memory impairment, especially in episodic memory (Squires, 1983). The RAM gains 
psychological validity from observations of similarities between the memory effects 
seen in humans, such as primacy and recency effects and proactive interference, and the 
behaviour of rats in the RAM (see Olton, 1987). 
Because of the above features, the RAM has been used extensively to investigate 
the psychological and neurobiological processes in memory. It has been used as a tool 
in behavioural toxicology (Walsh and Chrobak, 1987), behavioural teratology 
(Adams, 1986) and neurobiology (Jarrard, 1986). While not sensitive to every kind of 
neural insult, RAM performance displays an acknowledged sensitivity to lesions of the 
hippocampus and its afferent and efferent projections (Walsh and Chrobak, 1987; 
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Jarrard, 1986). Standard RAM procedures employ positive reinforcement and thus 
avoid the problems with emotional variability that confound the interpretation of 
avoidance tasks. 
The RAM represents a complex test of learning and memory. Complex tests 
increase the chance of detecting performance differences, especially subtle differences 
in cognition that may not show up on less demanding tasks (Olton, 1983b). In order to 
make the RAM task a sufficiently demanding task, the present study used a 12 arm 
RAM with six of the arms baited and six of the arms unbaited. The baited and 
unbaited procedure used in study were first employed by Olton and Papas, (1979) to 
distinguish between two theoreticaly different types of memory: working memory and 
reference memory. Working memory has been described as the memory of information 
which is pertinent to only one instance or trial, whereas reference memory is a more 
general type of memory which is relevant to a large number of similar instances or 
trials (Olton, 1983b; Morris, 1983). These constructs are not considered to be completely 
separable as working memory tasks (where is the food?) always require the 
performance of some behaviour which requires reference memory (run to the end of the 
arm to find the food). Olton and Papas proposed that ideal performance in the RAM 
with baited and unbaited arms requires the both working and reference memory. The 
rat requires a working memory of events in the current trial to determine whether it 
has already been to a baited arm. Reference memory is needed to learn the general 
rule that that no matter what trial the rat is in and no matter what the rat has 
already done in the present trial, it will not find food on the first entry and subsequent 
re-entries to some arms. However these operational definitions of working and 
reference memory are not universally accepted as Jarrard (1986) considers that 
remembering not to re-enter an unbaited arm within a trial is a working memory task. 
To avoid this unresolved issue, the present study will refer to memory errors by their 
operational definitions: re-entries to baited arm, initial entries to unbaited arm and 
re-entries to baited arms. 
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As well as learning, behavioural teratology studies frequently sample a variety of 
types of behaviour, including sensory functions, motor abilities, measures of 
development, activity, emotional behaviour and exploratory behaviour (see Adams, 
1986; Rodier, 1978). The present study chose to examine the effects of prenatal 
exposure to APM on exploratory behaviour, and in so doing possibly to extend the 
tentative findings of Gershbein et al. (1987), that low dose postnatal exposure to APM 
reduced exploratory behaviour. 
Gershbein et al. (1987) used hole-poking on a hole-board test as a measure of 
exploratory behaviour, even though they considered the reliability of this test as a 
measure of exploration had not been established. Hole-poking in a novel environment 
is believed to measure exploration as change in the environment is presumed to 
increase exploratory behaviour and one form of exploratory behaviour in the rat is a 
tendency to dip its head into a dark hole (Mackintosh, Chance and Silverman, 1977). 
But as the animal is forced into the novel environment, what is measured is the rat's 
behaviour in the presence of inescapable novelty and not it's novelty seeking 
behaviour (Robbins, 1977). The hole-poking task tries to separate whole body 
locomotion from discrete head dipping behaviour, but hole poking scores are highly 
influenced by the activity level of the animal (Robbins, 1977). Studies with 
amphetamine have shown that hole-poking behaviour can vary somewhat 
independently of activity level (File, 1978) but the level of activity of the animal 
remains a serious uncontrolled and unmeasured confounding factor. Indeed, the hole 
poke test has been used as a measure of activity only (Adams, 1986). 
The present study measured exploratory behaviour in the Hughes exploration box. 
This procedure overcomes many of the the limitations of the hole poke test. The 
Hughes exploration box consists of a Perspex box divided into two separate halves, 
each half being sub-divided into two cells. The animal is familiarized with one half 
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of the box and then, after a suitable habituation period, it is allowed access to the 
other, novel side of the box. As exploration always depends on the animal being 
active, the Hughes exploration box allows the simultaneous and independent 
measurement of exploratory behaviour and locomotor activity. A time sampling 
technique determines the amount of time spent in the familiar and the novel sides of 
the box and the percentage of time spent in the novel side of the box provides a 
measure of exploratory behaviour. A measure of locomotor activity is provided by a 
record of the total number of cells entered. The independence of the measures of 
activity and exploration have been confirmed by observations of increased, decreased 
and unchanged exploration with each of increased, decreased and unchanged activity 
(see Hughes and Pither, 1987). 
Changes in exploration are inferred only when (i) the activity measure remains 
constant while the exploration measure changes, (ii) the activity measure changes 
while the exploration measure remains constant, or (iii) both the exploration measure 
and the activity measure vary but in opposite directions. Thus, the Hughes 
exploration box is less affected than the hole-poke test by the problem of activity 
confounding the measure of exploratory behaviour. Also, the Hughes exploration box 
provides a true measure of novelty seeking behaviour by allowing the rat to choose 






The present study used randomly derived albino, Wistar rats from the University 
of Canterbury Psychology Department colony. When the females were at estrus, as 
determined by regular vaginal examination, fourteen pairs of male and female rats, 
aged 126-146 days, were placed together in separate plastic cages, 46 x 29 x 16.5 cm 
high, with stainless steel lids. After mating was observed, the males were removed 
and the dams were randomly assigned to one of three groups. From day one of 
pregnancy until parturition, two groups were administered APM dissolved in their 
drinking water at concentrations of 0.05% (n=4 dams) or 0.10% (n=4 dams) by weight. 
The solutions were buffered with citric acid to a pH of 4.3 ± 0.2 as APM is maximally 
soluble and degrades very slowly at this pH (Reynolds, 1982; Gossel, 1984). The 
drinking water of the third, control group (n=6 dams) was buffered to the same pH. 
All dams received these solutions ad. libitum throughout gestation and until 
parturition. Every three days, the body weight of the dams and the weight of the 
solution was recorded and all three solutions were changed. Drinking solutions were 
made up fresh every 6 days and stored at 4 °C . The APM used in the present study was 
kindly supplied by Sutton Distributors, Auckland, New Zealand. The APM was found 
to be pure when examined by nuclear magnetic resonance spectroscopy in the Chemistry 
Department of the University of Canterbury, Christchurch, New Zealand. 
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From the body weights and solution weights, the dose of APM consumed was 
calculated for the dams from which the experimental subjects were taken. Across 
days, the 0.05% APM dams consumed an average of 60.3 ± 6.2 mg/Kg/ day (mean ± 
S.D.) of APM and the 0.10% APM dams consumed an average of 123.6 ± 13.03 
mg/Kg/ day of APM. 
The experimental subjects were born at 20-23 days after mating and litter sizes 
ranged from 9 to 14 pups. At birth, experimental solutions were removed and fresh 
drinking water was supplied to all groups. Within 24 hours of birth, all litters used in 
the experiment were cross-fostered to control group dams that has also delivered a 
litter within 24 hours. If a suitable control dam was not available to accept a litter 
within this 24 hr period, the litter was not used in the experiment. 
Intraspecific genetic variation can cause behavioural differences between members 
of the same species and this genetically determined behavioural variation can be a 
confounding factor in behavioural teratology studies. To control for this genetic effect, 
behavioural teratology studies increase the genetic variation of experimental groups 
by taking few, or ideally only one, subject from each experimental litter. Controlling 
genetic variation is a resource intensive requirement and a balance must be found where 
this effect is adequately balanced without an excessive use of resources. In the present 
study, it was decided that these demands could be adequately met by taking three 
offspring form each of three experimental litters. Of the original 14 dams, five (two 
control dams, two 0.05% APM dams and one 0.10% APM dam) did not produce successful 
litters and two of the control litters were not used due to a lack of suitable cross-foster 
mother within 24 hours of birth. One 0.05% APM dam gave birth to seven female, but 
no male, pups. Table 2.1 (p. 38) shows the size and genetic composition of the groups. 
The male and female control and 0.10% APM groups were each made up of three rats 
from each of three litters. However, the nine 0.05% APM female rats came from two 
litters and the six 0.05% APM males came from only one litter. 
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Table 2.1 
Summary of Experimental Group Size, Number of Litters in the Groups and the 









60.3 ± 6.3 
123.6± 13.0 






Number of Litters 
in group (rats per litter) 
Males Females 
3 (3,3,3) 3 (3,3,3) 
1 (6) 2 (4,5) 
3 (3,3,3) 3 (3,3,3) 
Subjects were weaned at 25-28 days and group housed in plastic cages, 46 x 29 x 16.5 
cm high, with stainless steel mesh lids. Each cage contained three same-sex rats from 
the same experimental group and, where possible, the rats were from different litters. 
A record was kept of the litters which the animals came from so that the 
experimental results could be analysed for the presence of litter effects. The rats were 
housed in a room maintained at an ambient temperature of 24 ± 1 °C on a reversed 12-
hr light-dark cycle with lights off 6 am to 6 pm. Before the RAM testing began, the 
reversed light dark cycle was adjusted to lights off 12 pm to 12 am to accommodate the 
availability of the experimenter. 
Standard dry rat food and drinking water were available ad libitum from 
weaning until after the Hughes exploration box testing. The RAM procedure requires 
the body weight of the rats to be reduced to a percentage of their free feeding weight. 
As the rats in the present study were young and still growing rapidly, their body 
weight was maintained at 80 to 85 percent of their growth-adjusted expected body 
weight during testing in the RAM. The expected body weight figure was calculated for 
each sex from the body weights of three male or three female control group rats which 
were allowed ad. libitum access to food throughout the experiment. During the weight 
reduction and pretraining phase, all rats were weighted daily and the quantity of 
food that was required to maintain the growth adjusted weight of the rats was 
determined. During the RAM testing, the rats were fed the predetermined quantity of 
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food daily and were weighed, on average, every three days. Any below-weight rats, 
relative to cage-mates, were allowed additional food in a separate cage. 
2.1.2. Apparatus 
Hughes Exploration Box 
This test simultaneously employed four identical exploration boxes. Each box was 
40x40 cm square, 20 cm high and constructed of Perspex sides, two half-sized Perspex 
hinged lids and four quarter-sized galvanized metal floor plates. Each box was 
divided into four equal sized quadrants by opaque Perspex walls. Each wall had a 
7.5x20 cm opening centered at the middle of the quadrant, which allowed access 
between adjacent quadrants. Two opaque guillotine doors could be lowered from above 
to block two of the openings and divide the box into left and right sides. Each box was 
enclosed in a sound proof ventilated chamber with an internal volume of 250 litres. 
The ventilator fan provided a background masking noise in the box of 80-85 dB (Dawe 
Sound Level Meter, Type No.1400E, weighting 'C'). Each box was illuminated by a 
centrally mounted 8 W fluorescent tube which provided a light intensity, close to the 
centre of the box, of 600 lux ± 5% {Toshiba SP1-5 Photocell Illuminometer). 
Observation of the rats were made through a small one way window in the front wall 
of each chamber with the door of the chamber closed. 
Radial Arm Maze 
The central platform of the maze was a wooden dodecahedron of 38 cm diameter, 
painted black and raised 65 cm above the floor. The 12 unpainted aluminium arms 
(65.5 x 8.5 cm) radiated out from the 12 faces of the central platform. Each arm had 3.5 
cm high sidewalls, and a 23cm high perspex wall along the central 20 cm of one side to 
ensure that the rat returned to the centre of the maze before choosing another arm. 
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There was a recessed food well drilled in a black painted wooden block (5 x 8.5 x 1 cm) 
at the end of each arm. Access to the arms was governed by 7cm wide transparent 
Perspex guillotine doors mounted on a 38 cm high wooden frame that was attached to 
corners of the central platform. The doors could be remotely raised or lowered by a 
system of overhead strings. 
The 12-arm radial maze was located to one side of a 2.3 x 2.8 m room. The 
experimenter sat in one comer next to a table and an Apple MacIntosh SE computer. A 
"hypercard" stack was written for the computer to semi-automate the data recording 
and scoring. The room was illuminated by two 8 W fluorescent tube desk lamps 
positioned along the central axis of the maze on a shelf 2.15 m above the floor. These 
lamps provided a light intensity at the centre of the maze of 95 ± 5 lux. The 
background noise level in the room, mainly from the computer and the air conditioning, 
was measured at 57 - 63 dB. 
2.1.3. Procedure 
Hughes Exploration Box 
At 42 to 48 days of age, each of the 51 experimental rats were tested once in one of 
the four exploration boxes. To control for possible differences in the boxes, near-equal 
numbers of rats from each condition and sex were tested in each of the four boxes. The 
testing took place over a four day period between 9 am and 1 pm. The testing order and 
side into which the rat was initially placed was balanced across conditions and sex to 
control for any possible day or time of day effects. To control for the possible effect of 
unfamiliar odour trails, male rats were always followed by female rats, and vice 
versa, and no two rats from the same cage were tested in the same exploration box. 
The day before the experiment began, eight rats which were not used in the 
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experiment were tested in the boxes to ensure unfamiliar odours were present for the 
first experimental rats. During the procedure, the experimenter was blind as to the 
experimental condition of the rats. All the rats which were required for each day of 
testing were transported in their home cages to the testing room before testing began. 
Testing began with the two guillotine doors in place to divide the box into two 
separate halves. The rat was placed alone in one side of the box and the box lid and 
chamber door were closed. After 60 minutes, the rat was removed from the box to a 
holding container on top of the chamber, the guillotine doors were removed to allow 
access to the unfamiliar side of the box, and the rat was replaced in the quadrant of 
the box from which it was taken. The lid of the box and the door of the chamber were 
closed. Behavioural recording began about 30 seconds after the change-over operation 
was completed. Each rat was observed through the one way window a 10 minute 
period. During this period a record was made of: 
(i) locomotor activity, based on a continuous cumulative record of the 
total number of quadrants entered by the rat. A quadrant was 
defined as entered if all four feet crossed into it. 
(ii) whether the rat was (a) in the familiar or novel half of the box 
(novelty preference) and (b) whether it was rearing, grooming or 
engaging in neither of these behaviours. These measures were 
recorded at the end of five second intervals. 
Radial Arm Maze 
The rats were pretrained in the RAM during the weight reduction period described 
above. Pretraining continued until each rat had taken food at least once from every 
arm. Initially all doors were held open and a small quantity of the food reward was 
placed in every arm close to the centre of the maze. 'Nestles' chocolate 'Mini Morsels' 
were used as the reward. Gradually the food was available further down the arms to 
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the food wells and the raising and lowering of the doors was introduced. All rats were 
pretrained in eight sessions. 
The rats were 64 - 67 days old when the first session of radial maze testing began. 
All 51 rats were tested for 40 sessions over a period of 68 days. The same testing order 
was used in all sessions. The order was balanced across groups for possible influences of 
time of day effects. The same relative pattern of baited and unbaited arms was used 
for all rats, but the pattern was rotated around the maze arms according to a randomly 
assigned rotation number, between 1 and 12, that was given to each rat. The first, 
third, fourth, seventh, eighth and nineth arms which followed the assigned rotation 
number arm, in a clockwise direction, were baited, while the other six arms were 
unbaited. This procedure was used to control for possible odour trails and differences in 
the complexity of remembering different bait patterns. 
During the procedure, the experimenter was blind as to the experimental condition 
of the rats. For each session, a third of the rats were transported to the testing room at 
a time. Each trial began with the baiting of the correct arms for the rat, as displayed 
by the computer. The rat was placed in the centre of the maze for about five seconds 
before the doors were raised. When the rat entered an arm with four feet, all the 
doors were closed except for the one leading to the arm which the rat had entered. 
This door was closed when the rat returned to the centre of the maze. All doors 
remained closed for five seconds and then they were all re-opened. 
Each time the rat entered an arm or the centre of the maze, the experimenter 
entered the rat's new location on the computer by pressing the appropriate key. The 
computer was programmed to record which type of response the rat had made and the 
time elapsed. Responses were coded as: initial entries to baited arms, re-entries to 
baited arms, initial entry to unbaited arms and re-entries to unbaited arms. Also, a 
computer generated 'beep' indicated the end of the 5 second 'doors-closed' period, and 
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the computer visually indicated when the rat had successfully completed the maze 
trial (eaten all rewards) or when the maximum time limit for the trial was over. The 
maximum time limit to obtain the six rewards was 15 minutes, after which the trial 
was terminated. If the trial was terminated and the rat had entered less than 15 
arms, the data for that trial for that rat were excluded from analysis. If the rat had 
entered at least 15 arms, the data were included in the analysis, but only after it was 
adjusted to account for the number of baited arms that the rat had not visited. This 
adjustment involved (i) scoring the maximum of six for the initial entries to unbaited 
arms, and (ii) separately multiplying the number of re-entries to baited arms and re-
entries to unbaited arms by the total number of baited arms (six) and dividing by the 
number of baited arms which were not entered. 
Three types of error scores and two time measures were calculated for each rat on 
each trial. The error scores were (i) the number of initial entries to unbaited arms, (ii) 
the number of re-entries to unbaited arm, and (iii) the number of re-entries to baited 
arms. The time measures were (i) the mean time taken to visit each arm (total session 
time divided by the number of arms visited) and (ii) the mean latency to enter an arm 
after the doors were raised for the first six arm visits of the trial. Only six arm visits 
were considered as perfect performance on the maze required only six arm visits. 
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2.1.4. Statistical Analyses 
Hughes Exploration Box 
One sample t-tests were performed on the familiar and novelty preference 
measures for each group (Dose X Sex). Separate two-way analysis of variance (Dose X 
Sex) was performed on each of the novelty preference, rearing, grooming and 
ambulation measures. 
Radial Arm Maze 
For each rat, each of the three error scores and two time measures were averaged 
over blocks of five sessions. Each measure was then analysed by a three-way repeated 
measures analysis of variance (Dose X Sex X Blocks) with Blocks as the repeated 
measure. When significant treatment interaction was obtained, a one way analysis of 
variance (Dose) was performed on each Block with Neuman-Keuls tests of significance 
between paired means. Where litter effects were suspected, a similar one way 
ANOVA was performed with Neuman-Keuls test, with litter as the factor. 
44 
2.2. Results 
Hughes Exploration Box 
The effects of Dose on all behaviours is shown in Figure 2.1 (p. 46). Extreme cases 
were excluded from analysis, as defined by cases when the animal failed to enter the 
novel side of the exploration box, the rat apparently being asleep. For each 
experimental group (Dose X Sex), Table 2.2 (p. 47) shows the remaining group size and 
the mean and standard deviation of the ambulation score and observations of novelty 
preference, rearing and grooming. The one-sample t-tests for novelty preference 
(chance= 60) revealed a significant preference for novelty in the male control group, 
t(7)=3.96, p<.01, female control group, t(7)=4.94, p<.01, male 0.10% APM group, 
t(8)=4.34, p<.01, female 0.10% APM group, t(7)=4.53, p<.01 and the female 0.05% 
APM group, t(8)=4.73, p<.01. However the male 0.05% APM did not show a preference 
for novelty, t(3)<1.0, p>.10, and this may be a reflection of the small group size and 
that two of the rats in this group were excluded as extreme cases. The standard 
devaitions of the male 0.05% APM (S.D.=33.2) was considerably higher than the 
standard deviations of all other groups (12.S!S:S.D.!S:20.7) but the male 0.05% APM 
group did contain the two lowest scores out of all groups. A one-way ANOV A 
indicated that there was no litter effect on novelty preference, F(7,38)<1.0, p>.10. 
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Figure 2.1: 
Hughes Exploration Box: Mean Five Second Observations of Novelty Preference, 
Rearing and Grooming, and Total Cells Entered for Control, 0.05% APM and 0.10% 
APMGroups. 
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Table 2.3 (p. 47) shows the results of separate two way ANOVAs (Dose X Sex) for 
each dependent measure. These ANOV As revealed no significant Dose effect on 
novelty preference, F(2,40)=1.61, p>.10, rearing F(2,40)=1.7, p>.10, grooming 
F(2,40)<1.0, p>.10 or ambulation F(2,40)=1.52, p>.10. Females showed a significantly 
greater preference for the novel side the of exploration box than males, F(l,40)=8.35, 
p<.01, but when the novelty preference of the control and 0.10% APM groups were 
compared with an unpaired t-test, the greater novelty preference displayed by the 
females was no longer significant, t(31)=1.882, p=.069. There were no other significant 




Remaining Group Sizes, Means ± Standard Deviations For All Exploration Box 
Dependent Measures (Extreme Values Omitted) 
Measure Group Males Females 
n Control 8 8 
0.05%APM 4 9 
0.10%APM 9 8 
Novelty: Pref. Control 85.4 ± 18.1 92.5 ± 18.6 
0.05%APM 61.3±33.2 90.2± 19.0 
0.10%APM 78.1 ± 12.5 93.4 ±20.7 
Rearing Control 20.6±7.6 21.6±3 .o 
0.05%APM 13.8±4.7 19.9 ±8.7 
0.10%APM 16.9±6.7 19.0±5.4 
Grooming Control 5.4±3.0 9.4 ± 8.9 
0.05%APM 7.8±6 .7 5.7±5.0 
0.10%APM 6.4 ±8.2 6.1 ± 4.4 
Ambulation Control 26.4±9.9 27.0± 8.2 
0.05%APM 22.0±5.8 22.0 ± 9.0 

















28.5 ± 11.0 
Summary of ANOVA Results For All Exploration Box Dependent Measures 
Measure Source df: F p 
Novel Pref. Dose 2,40 1.61 0.2134 
Sex 1,40 8.35 0.0062 ** 
SexxDose 2,40 1.06 0.3554 
Rearing Dose 2,40 1.70 0.1956 
Sex 1,40 2.41 0.1282 
SexxDose 2,40 0.55 0.5831 
Grooming Dose 2,40 0.12 0.8906 
Sex 1,40 0.07 0.7914 
SexxDose 2,40 0.82 0.4497 
Ambulation Dose 2,40 1.52 0.2304 
Sex 1,40 0.13 0.7192 
SexxDose 2,40 0.25 0.7787 
Note: ** p < .01 
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Radial Arm Maze 
Twenty-three cases (1.1 % of all cases) 
were excluded from the analysis; 22 cases 
were excluded as the sessions were 
terminated and the rats had visited less 
than 15 arms of the maze and one case was 
excluded as a female 0.10% APM rat had a 
seizure in the maze. Table 2.4 shows the 
groups that the excluded cases came from. 
Note that each case refers only to one trial 
of one rat. 
Table 2.4 
Radial Arm Maze Cases 










The effects of Dose and Sex on the three error scores are shown in Figures 2.2 (p. 49) 
and 2.3 (p. 50). Table 2.5 (p. 51) shows a summary of the three way ANOV As (Dose X 
Sex X Blocks) with repeated measures (Blocks). The ANOV As show that APM had no 
effect on the number of re-entries to baited arms, the number of initial entries to 
unbaited arms or the number of re-entries to unbaited arms. For these three error scores, 
there was no effect of Dose, F(2,45)<1.00, p>.10, Sex, F(l,45}~.13, p<.10, and no Dose X 
Sex interaction, F(2,45)<1.00, p>.10, although there was an indications that Sex 
tended to affect initial entries to unbaited arms, F(2,45)=3.13, p<.084. Within subjects, 
all three error scores significantly decreased across sessions, F(7,315)~128.87, p<.001. 
However, there were no significant interaction effects of Dose X Blocks, F(14,315)~1.32, 
p>.10, Sex X Blocks, F(7,315}<1.00, p>.10, or Dose X Sex X Blocks, F(14,315)~1.00, 
p>.10. These analyses and Figure 2.2 combine to shows that, by the end of the 
experiment, all groups were making few errors and had learned the maze task to a 
high degree of proficiency. Also, the rate of acquisition of the RAM task was not 
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Table 2.5 
Summary of ANOVA for Radial Arm Maze Error Scores 
Measure Source df: F £ 
Re-entries Between Subjects 
To Baited Dose 2,45 0.62 .543 
Arms Sex 1,45 1.34 .253 
DoseXSex 2,45 0.64 .534 
Within Subjects 
Blocks 7,315 144.60 .000 ** 
Dose X Blocks 14,315 1.32 .192 
SexX Blocks 7,315 0.71 .665 
Dose X Sex X Blocks 14,315 0.59 .870 
Initial Entries Between Subjects 
To Unbaited Dose 2,45 0.99 .380 
Arms Sex 1,45 3.13 .084 
DoseXSex 2,45 0.48 .625 
Within Subjects 
Blocks 7,315 251.70 .000 ** 
Dose X Blocks 14,315 0.99 .463 
SexX Blocks 7,315 0.40 .905 
Dose X Sex X Blocks 14,315 0.91 .543 
Re-entries Between Subjects 
To Unbaited Dose 2,45 0.19 .831 
Arms Sex 1,45 0.23 .633 
DoseXSex 2,45 0.72 .490 
Within Subjects 
Blocks 7,315 128.87 .000 ** 
Dose X Blocks 14,315 0.71 .763 
SexX Blocks 7,315 0.78 .602 
Dose X Sex X Blocks 14,315 1.00 .458 
Notes: ** p<.01 
Figure 2.4 (p. 53) shows the mean arm visit time expressed as a function of Dose and 
Sex. Table 2.6 (p. 54) shows a summary of the three way ANOV As (Dose X Sex X · 
Blocks) with repeated measures (Blocks). For the mean arm visit time measure, there 
was a signifcant between-subjects effect of Dose, F(2,45)=3.40, p<.05, and a significant 
within-subjects Dose X Blocks interaction, F(14,315)=2.71, p<.01. Neuman-Keuls tests 
of significance between rank ordered means (a.=.05) were performed on the mean of the 
arm visit times over all 40 sessions and revealed that the 0.10% APM group took 
significantly less time in the arms that the 0.05% APM group, but the mean time taken 
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by the control group was between the 0.10% APM and 0.05% APM groups and was non-
significantly different from either. A one way ANOV A performed on the average 
time scores over the each of the blocks of sessions revealed a significant effect of Dose 
on the second, third and fourth blocks of sessions (respectively sessions 6-10, 11-15, 16-
20), F(2,48)~3.90, p<.05. Neuman-Keuls tests of significance between rank ordered 
means (a.=.05) showed that the 0.10% APM group took significantly less time to visit 
the arms than the 0.05% APM group on blocks two, three and four and the the 0.10% 
APM group took significantly less time than the control group on block three. Also, t.'1e 
control group took significantly less time than the 0.05% APM group on block two. 
There were no other significant effects of this measure. Taken together, there results 
suggest the time taken to visit the arms decreased to a fairly stable period by the end 
of the tenth session, and that the significant Dose X Blocks interaction was largely due 
to the 0.05% APM group taking longer than the 0.10% APM group on some of the early 
blocks of sessions. A one-way ANOV A of the mean arm visit times over all 40 sessions 
by litter revealed that the litter failed to reach an acceptable level of significance, 
F(7,43)=2.17, p=.056 and, more importantly, Neuman-Keuls tests showed that while 
one 0.05% APM litter took significantly longer than one control group litter and one 
0.10% APM group litter, none of the litters were significantly different from any of the 
other litters in the same Dose. This suggests that the observed effects can not be 
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Table 2.6 
Summary of ANOVA for Radial Arm Maze Time Measures 
Measure Source df: F E 
Mean Between Subjects 
Visit Dose 2,45 3.40 .042 * 
Time Sex 1,45 0.65 .426 
DoseXSex 2,45 2.76 .074 
Within Subjects 
Blocks 7,315 102.62 .000 ** 
Dose X Blocks 14,315 2.71 .001 ** 
SexX Blocks 7,315 1.60 .136 
Dose X Sex X Blocks 14,315 0.86 .607 
Arm Choice Between Subjects 
Latenc~ Dose 2,45 4.80 .013 * 
{first six entries} Sex 1,45 0.00 .997 
DoseXSex 2,45 0.22 .805 
Within Subjects 
Blocks 7,315 33.76 .000 ** 
Dose X Blocks 14,315 2.67 .001 ** 
SexX Blocks 7,315 1.03 .411 
Dose X Sex X Blocks 14,315 0.85 .610 
Notes: * p<.05 
** p<.01 
Figure 2.5 (p. 56) shows the group means for the mean arm entry latency, after the 
doors were opened for the first six arm entries, by Dose and Sex. Table 2.6 shows a 
summary of the three way ANOVAs (Dose X Sex X Blocks) with repeated measures 
(Blocks). On the arm entry latency measure, there was a signifcant between subjects 
effect of Dose, F(2,45)=4.80, p<.02, and a significant within subjects interaction effect 
of Dose X Blocks, F(14,315)=2.67, p<.01. Neuman-Keuls tests of significance between 
rank ordered means (a=.05) were performed on the mean of the arm entry latencies 
over all 40 sessions and revealed that the 0.10% APM group took significantly less 
time to enter an arm that the control group, but the mean time taken by the 0.05% APM 
group was between the control and 0.10% APM group times and was non-significantly 
different from either. A one way ANOV A performed on these latency scores over each 
of the blocks of sessions revealed a significant effect of Dose on the first four blocks of 
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sessions, F(2,48)~3.33, p<.05. Neuman-Keuls tests of significance between rank ordered 
means (a=.05) showed that the 0.10% APM took significantly less time to enter the 
first six arms than the control group on the first, third and fourth blocks and the 0.10% 
APM took significantly less time than the 0.05% APM group on the first, second and 
third blocks. The 0.05% APM took significantly less time than the control group on 
the third block. Although Figure 2.5 (a) shows the the controls took longer to enter the 
arms on blocks five and six than the APM groups, neither the ANOV As nor the 
Neuman-Keuls tests showed that these differences were significant. There were no 
other significant effects of this measure. Taken together, there results suggest that the 
mean latency to enter the first six arms decreased quickly for all groups but then the 
time taken by the control group increased slightly before becoming non-significantly 
longer than the APM groups for most of the remaining sessions. The significant Dose X 
Blocks interaction was largely due to the 0.10% APM group taking less time to enter 
the arms than the control groups over the first six blocks. 
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Figure 2.5. 
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Figure 2.6 (p. 58) shows the weights of the rats by Dose and Sex and Table 2.7 
shows a summary of the three way ANOV As (Dose X Sex X Blocks) with repeated 
measures (Blocks). Figure 2.6 (a) suggests that the 0.05% APM group weights may 
have been slightly lower than the weights of the control and 0.10% APM groups, but 
this is probably a reflection of there being relatively fewer of the heavier males in 
the pooled male and female 0.05% APM group compared to the control and 0.10% APM 
groups. A three way ANOV A (Dose X Sex X Blocks) with Blocks as a repeated 
measure showed that the weights of the rats were not affected by Dose, either 
between subjects (Dose X Weight, F(2,45)=1.861, p>.10) or within subjects (Dose X 
Blocks, F(14,315)<1.0, p>.10, Dose X Sex X Blocks, F(14,315)<1.0, p>.10). There was a 
significant between subjects effect of Sex on the weight of the rats, F(2,45)=261.36, 
p<.001, and a significant within subjects interaction effect of Sex X Blocks, 
F(14,315)=24.35, p<.001. These results show that the male rats gained significantly 
more weight than the females, but the weight gain of either sex was not affected by 
the Dose condition of the rats. 
Table 2.7 
Summary of ANOVA for Body Weights During Radial Arm Maze Testing Period 
Measure Source df: F p 
Bodi Weight Between Subjects 
Dose 2,45 1.861 .167 
Sex 1,45 261.34 .000 ** 
DoseXSex 2,45 2.373 .105 
Within Subjects 
Blocks 7,315 642.81 .000 ** 
Dose X Blocks 14,315 0.70 .773 
SexX Blocks 7,315 24.35 .000 ** 
Dose X Sex X Blocks 14,315 0.26 .997 
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3.1. Main Findings 
3.1.1. Hughes Exploration Box 
The results of the present study show that prenatal exposure to low doses of APM 
(60 and 120 mg/Kg/ day) does not affect exploratory behaviour in rats, as measured in 
the Hughes exploration box. The male 0.05% APM group was the only group not to 
show a significant novelty preference, and the larger standard deviations of this 
group, compared to all other groups, suggests that this may be partly due to the very 
small remaining group size (n=4) after two of the rats in this group were excluded as 
extreme cases. However, this group did contain the lowest novelty scores across any 
group and so the increased variance does not adequately explain the finding of a lack 
of novelty preference in the male 0.05% APM group. When considering both APM 
groups and the control group, females displayed a significantly greater novelty 
preference than males, but when considering only the control and 0.10% APM groups, 
this trend was no longer significant. This shows that the statistical difference 
between sexes was influenced by the low novelty preference of the 0.05% APM group. 
An analysis of this measure by litter showed that this effect was not due to a litter 
effect and it remains unclear why this male group scored so lowly on the novelty 
measure. There is no reason to discount the sex effect, especially as the trend towards 
the effect existed when the 0.05% APM groups were not considered, even though the 
trend did not quite reach statistical significance. 
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As females displayed both a significantly greater novelty preference and 
unchanged ambulation scores, it can be can be concluded that they displayed more 
exploratory behaviour than males. This is an unusual finding and, to the knowledge of 
the author, there are no reports of similar findings in the literature3. The results of 
this study are also unusual in that they do not support the typical observations in the 
Hughes exploration box that females are more active and rear more than males (e.g., 
Hughes and Pither, 1987; Hughes and Swanberg, 1970) and males groom more than 
females (Hughes, 1970). However a sex difference in grooming is not consistently 
reported in the literature (e.g., Hughes and Pither, 1987) and other differences 
between the present study and the literature may possibly be related to the age of the 
animals in the present study (42-48 days). But, while Hughes (1970) reported no sex 
difference between grooming in young rats (M=47 days), he also reported no sex 
difference on novelty preference and that females had higher ambulation scores than 
males, although ambulation scores were lower for young animals than older animals 
(M=189 days). Gearly, age effects do not account for all of the unusual findings in the 
exploration box. 
3.1.2. Radial Arm Maze - Error Scores 
The present study does not support the hypothesis that the prenatal exposure of 
rats to the low doses of APM used in this experiment may impair spatial memory in 
the RAM. On the RAM test, there were no dose, sex or interaction effects on any of the 
three error scores: re-entries to baited arms, initial entries to unbaited arms and re-
entries to unbaited arms. By the last block of sessions, all groups were making few of 
any of the classes of errors and hence all groups showed that they had learned the 
task to a high degree of proficiency. While the shape of the learning curves depicted 
by the error scores across blocks of sessions were not subjected to statistical analysis, 
3 Hughes, personal communication. 
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the initial entries by unbaited arms errors appear to decrease in a linear fashion 
whereas the re-entries to both baited and unbaited arms appear to decrease at a more 
exponential or hyperbolic rate. These somewhat tenuous observations could be 
interpreted as supporting the notion that RAM performance is dependent on two 
different types of memory and that the same type of memory is required for making re-
entries to both baited and unbaited arm while a different type of memory is required 
for making initial entries to unbaited arms. This would support the working and 
reference memory distinctions made by Jarrard (1986). 
3.1.3. Radial Arm Maze -Time Effects 
Arm Visit Time 
The results revealed that prenatal exposure to low doses of APM affected the time 
taken by rats to complete some aspects of the RAM task. For the mean arm visit times, 
the results of the one way ANOV As and the Neuman-Keuls tests of significance on the 
means of all 40 sessions and the eight blocks of sessions suggest that the interaction of 
dose by blocks was largely due to the 0.05% APM group taking longer than the 0.10% 
APM group on some of the early blocks of sessions. While Figure 2.4 (a) (p. 53) shows 
the 0.10% APM took less time in the arms than the other groups, the means of the 
control and 0.10% APM groups differ significantly on only one block of sessions and not 
across the mean score of all 40 sessions. This discounts the possibility of a simple dose-
response effect on this measure. One explanation for this observed difference between 
the 0.05% APM group and other groups is that the reduced genetic variability in the 
0.05% APM groups could exert itself as a difference between litters on this measure. 
The analysis of the mean arm visit times of the 40 sessions by litter revealed an non-
significant trend towards litter differences and the Neuman-Keuls tests revealed that 
the none of the litter means were significantly different from any other litters of the 
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same Dose. However, the small number of litters in each group, and especially the 
0.05% APM group, would make it very hard to separate a litter effect from a dose 
effect. Nevertheless, litter differences do not seem to explain the unusual relationship 
between dose and mean arm entry time. 
Arm Entry Latency 
The results for the initial arm entry latencies appear to exhibit a simple dose-
response relationship but are not easily explained in terms of behavioural 
mechanisms. The one way ANOV As and Neuman-Keuls tests for the blocks of sessions 
suggest that the interaction effect of dose by blocks was largely due to the 0.10% APM 
groups taking significantly less time to enter the arms than the control groups over the 
first half of the blocks. A similar effect over the later half of the experiment may 
have been obscured as the time taken by all rats aproached an asymptote and the 
relative significance of the error created by the reaction time of the experimenter 
increased. During five of the first six blocks, the arm entry latency for the 0.05% APM 
groups fell between the control and 0.10% APM groups and on two of these occasions the 
0.05% APM latency was significantly different from either one or both of the control 
and 0.10% APM groups. Taken together, these findings suggest a dose-response 
relationship on the arm entry latency measure. 
A behavioural interpretation of the arm entry latency finding is difficult and, to 
the knowledge of this author, no previous studies have recorded this aspect of RAM 
performance. One possible explanation of this finding would be that the 0.10% APM 
rats were more motivated than the control rats to search for food in the maze, but the 
results show that weight did not vary across dose. It is possible that the rats exposed 
to APM were hungrier despite their equal body weights but the Brunner et al. (1979) 
study reported no difference in the body weights of the free feeding offspring of rats 
whose mothers had exposed to up to 2 g/Kg/ day APM throughout gestation. If APM 
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did have a motivational effect on the rats, this in itself would be an interesting 
treatment effect. 
It is noteworthy that over the first four blocks of sessions, the 0.10% APM group 
showed shorter arm entry latencies than the control group but over the same blocks the 
mean arm visit time of the 0.10% APM group did not appear to be consistently longer 
than that of the control group. This, together with the lack of dose effect on 
ambulation in the exploration box, suggests that the 0.10% APM group were not just 
exhibiting an increased level of locomotor activity. Instead, the difference may 
reflect a difference in emotional reactivity to the sudden change in reward 
contingencies from the pretraining to the testing phases of the RAM task. During 
pretraining, several pieces of food were available at each arm but when the testing 
sessions began only one piece of food was available at only half of the arms. A rat 
which was more reactive to this sudden change in contingencies may have been 
adapted more quickly to the novel task of choosing between arms. However the lack of 
difference in the average time taken to visit the arms once again suggests that this is 
an inadequate explanation of the results. 
The results show that the 0.10% APM group took less time to enter the first six 
arms of each trial than the control group yet the analysis of the error scores in the 
RAM shows that the 0.10% APM group made no more errors than the control group. As 
the 0.10% APM group learned the RAM task as well as control group but took less time 
to choose the correct arms, it is tempting to speculate that this reflects an enhancement 
of the maze learning abilities of the 0.10% APM group. Indeed, ASP, and its structural 
and functional analogue GLU, are involved in the neurobiology of memory and recent 
research has suggested that low doses of these excitatory amino acids may enhance 
memory development and function. Low doses of MSG have been found to enhance 
memory function in some individuals with Alzheimers' disease (see Deutsch and 
Morihisa, 1988) and low dose MSG has been found to promote neuronal growth and 
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differentiation, in vitro, in neural cell cultures (Aruffo, Ferszt, Hildebrandt and 
Cervos-Navarro, 1987). Hence it is possible that prenatal exposure to low doses of 
excitatory amino acids, such as ASP and GLU, may enhance the development of neural 
systems involved in memory. However, within the context of prenatal exposure to 
APM, the animal is also exposed to PHE which is likely to exert a dose-dependent 
impairment of cognitive functions. Perhaps the effects of low doses of ASP and PHE 
may counter act each other to obscure any overall effect. If so, this could conceivably 
account for the lack of observed effect on RAM performance in the present study. This 
hypothesis could be investigated by future research which separately examines the 
effects of prenatal exposure to PHE and sub-excitotoxic doses of ASP or GLU on RAM 
performance. 
3.2. Contribution of the Present Study 
The results of the present study suggest that prenatal exposure to a low dose of 
APM reduces the arm entry latency of the first six arm visits in the 12-arm radial arm 
maze in rats. To the knowledge of the current author, this tentative finding is the first 
report of a behavioural effect of prenatal exposure to a low dose of APM. The only 
previous behavioural teratology studies of APM which the present author found 
(Mahalik and Gautieri, 1984; Brunner et al. , 1979) gave high doses of APM to the rat 
dams (between 1 and 5 g/Kg/ day) and found developmental delays of the offspring. 
However, both of these studies failed to use adequate cross-fostering procedures and 
therefore their findings could be due to an indirect effect of APM on the dams. Indeed, 
Brunner et al. (1979) cross-fostered control offspring to APM fed dams and the 
postnatal developmental delays in these animals led them to attribute the findings of 
their teratology study to the effects of postnatal exposure to APM. The present study 
is also the first behavioural teratology study of APM which employed an adequate 
cross-fostering procedure or a low dose of APM. 
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It has previously been believed that low doses of APM are unable to affect the 
fetus because of the natural occurrence of APM's metabolites (ASP, PHE and 
methanol), the inability of ASP to cross the mature placenta and the presumed 
inability of the intact peptide even to enter the mother. However, the tentative 
finding in the present study of a dose-response effect on arm entry latencies suggests 
that APM and/ or its metabolites do reach the fetus in sufficient quantities to induce 
some kind of functional change. It is well beyond the scope of the present study to 
decipher whether the offending agent is PHE, ASP or the intact APM peptide or to 
confirm or refute the hypothesis that APM released ASP may be able to pass through 
the undeveloped placental barrier. 
To convert the dose of APM consumed by the rat dams in this study to a human 
equivalent, the rat dose must be divided by six to account for the faster metabolic rate 
of rats (Pardridge, 1986). Therefore, the human dose equivalent to the 0.10% APM 
groups' consumption is about 120 mg/Kg/ day+ 6 = 20 mg/Kg/ day : less than two thirds 
of the American FDA expected daily intake figure! It must be cautioned that the 
findings of the present study may be due to chance. Clearly, the present study is 
urgently in need of replication. If the results of the present study are found to be a 
consistent effect of prenatal exposure to low doses of APM, then APM may be exerting a 
widespread but unrecognized effect of public health. 
3.3. Limitations of the Present Study 
The present study employed a range of control procedures which were found 
lacking in previous behavioural teratology studies in the literature. The present study 
employed adequate cross-fostering procedures to control for indirect maternal effects, 
the experimenter was blind to experimental condition of the rats, and testing orders on 
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both behavioural tests were alternated across Dose and Sex to balance for any possible 
circadian variations in behaviour. Both of the behavioural tests employed in the 
present study are well validated measures. In the Hughes exploration box, the 
familiar side of the box and the particular box used were balanced across dose and sex. 
In the RAM, response habits were controlled by using doors and possible extra-maze or 
intra-maze stimulus differences were balanced by randomly rotating the pattern of 
baited and unbaited arms around the maze. The same bait pattern was used in case 
different patterns were harder to learn than others. None the less, the findings of the 
present study must be considered within the context of its methodological problems and 
limitations. As noted in the method section, behavioural teratology studies should 
ideally take only one rat from each experimental and control group litter so that the 
genetic variability of the groups may be maximized and the problem of confounding 
genetic and prenatal determinants of behavioural variation may be minimized. In an 
attempt to make the most of limited resources, the present study attempted to take a 
maximum of three males and three females from three different litters to make 
experimental groups of nine rats with a reasonable degree of genetic diversity. 
However, the failure of two of the four 0.05% APM dams to produce viable litters and 
the birth of only female pups to another 0.05% APM dam resulted in the 0.05% APM 
groups coming from only two litters, one of these litters contributing 11 of the total of 51 
experimental rats and the male 0.05% APM group having only six rats. Hence the 
present study was a long way from the ideal one subject per litter. To some extent, 
these problems are lessened by the desired adequacy of the control and 0.10% APM 
groups, but it must be remembered that each of these groups is comprised of only three 
litters. It would be advisable for future studies to decrease the number of experimental 
subjects taken from each litter or increase the size of the experimental groups. 
Behavioural teratogenic effects may interact with developmental changes in the 
animal to produce behavioural impairment at one age of the animal but not at a 
different age. Thus, the findings of the present study are weakened by testing the 
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animals at only one age. Ideally, behavioural teratology studies should take a more 
longitudinal approach to behavioural sampling and investigate the behaviour of 
different groups of animals at different stages throughout their life-cycle. Future 
research may examine whether the dose-response relationship observed in the present 
study between APM and arm entry latencies in the RAM is displayed by older animals. 
Dose-response relationships in behavioural teratology are quite sensitive and 
relatively small changes in the dose of a teratogenic agent can change the nature of 
the observed response from no effect to a behavioural change, to a morphological 
change or even to death (Vorhees, 1986). As the dose zone for any particular effect is 
narrow, a further short-coming of the present study is that it used only two low dose 
levels and hence it was unlikely to reveal the dose-zone for any particular 
behavioural effect. However the tentative finding of a dose response relationship 
between APM and arm entry latencies suggests that the higher dose in the present 
study may represent the lower end of the dose zone for this effect. As the literature on 
phenylketonuria and excitotoxic amino acids show, respectively, that high doses of 
PHE and most probably ASP can exert teratogenic effects on rats in a range of 
experimental learning tasks (see Sections 1.3.2, 1.5), it is most likely that the lack of 
observed effect on spatial memory was due to the doses of APM used in the present 
study being too low to impair performance on the RAM task. 
The RAM and the Hughes exploration box are well validated robust tests that 
have been used previously in behavioural teratology studies (Hughes and Beveridge, 
1987; Adams, 1986). From these tests, it can be safely assumed that prenatal exposure 
to the low doses of APM used in the present study produces no impairment in spatial 
memory or changes in exploratory behaviour in young rats. However, these negative 
findings must also be considered within the context of the methodological limitations 
of the present study and these negative findings do not allow the conclusion that 
exposure to low doses of APM does not exert any other unmeasured behavioural 
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teratogenic effect. The inferences that can be made from a behavioural teratology 
study are limited to the empirically derived knowledge of what behaviours the tests 
have measured, the degree of damage required to the relevant neural system before 
these behaviours are affected and the extent that the animal may be able to 
compensate for any specific deficit. The possibility always remains that a 
behavioural effect has gone unobserved. While Vorhees and Butcher (1982) correctly 
point out that an exhaustive invesigation of the behavioural teratogenicity of a 
substance could virtually last forever, the striking lack of methodologically sound 
behavioural teratology studies with APM warrant considerable future research. 
3.4. Recommendations for Future Studies 
The experience gained in the present study suggests that future behavioural 
teratology studies will benefit from increasing the genetic variability of the groups by 
taking fewer than six subjects from each litter. The tentative findings of this study 
support the value of low dose behavioural teratology studies, but future studies would 
be able to contribute more to their area of research by employing more dose levels 
which are more widely spaced from each other than those in the present study. This 
would more readily establish the dose zone for any particular response. 
In the present study, the ability to measure the time spent in various parts of the 
maze was responsible for detecting the arm entry latency effect. However, time 
measurement was influenced by the response time of the experimenter. Also, the 
software which determined and recorded the time was only accurate to within one 
second. As the time taken by the rats to move around the maze decreased, these sources 
of uncontrolled, random error became more significant, and they may have helped to 
obscure a dose effect in the later blocks of the session. Future studies may overcome 
these problems by employing some kind of automated time and place measurement 
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system which is accurate to fractions of a second and does not rely on the response time 
of the experimenter. Perhaps a computer controlled automated RAM procedure, 
similar to that described most recently by Peele and Baron (1988), could be adapted to 
record separately the time elapsed in both the arms and the hub of the maze. 
The necessary replication of the present study would benefit from employing 
additional measures which would allow a more thorough assessment of the 
behavioural teratogenic effects of APM. A range of measures may provide some 
understanding of the exact behavioural dimensions that have been observed in this 
study as a variation in the arm entry latency measure. For instance, if open field 
testing was employed before other tests in the battery, the naive rat's behaviour 
during the initial trial could provide a measure of emotional reactivity while the rats 
behaviour over a number of trials could provide a measure of general activity level. 
As well as replication of the present study, the understanding of the behavioural 
teratogenic potential of APM would greatly benefit from more research in the 
following areas: 
(i) Behavioural teratology studies of PHE using a demanding RAM procedure 
would help determine the lower limits of the dose zone of PHE's adverse effect on 
cognitive development. This would contribute to the understanding of the risks 
associated with hyperphenylalanemia as well as enabling a more accurate assessment 
of the likely effects of maternal APM consumption of the developing fetus. 
(fi) Examining the effects of prenatal and postnatal exposure to ASP using a 
demanding RAM procedure would investigate the hypothesis that low doses of ASP or 
GLU may in fact facilitate the development of the neural systems involved in memory. 
Given the known adverse consequences of higher doses of excitatory amino acids, a 
thorough investigation would be required to establish the dose zones of the 
hypothesised beneficial effects and known adverse effects. Also, longitudinal designs 
would be recommended to determine whether the positive or negative effects of these 
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agents may vary over the age of the animal. If low doses of ASP can exert a beneficial 
effect of the developing neural systems of memory, then the effect of APM released 
ASP may mask the possible adverse effects of prenatal exposure to APM released PHE. 
(iii) The biological investigation of the transfer characteristics of the 
undeveloped placenta would be of considerable benefit to most teratology 
investigations. Knowledge of the undeveloped placenta's transfer of ASP would 
enable more informed and hopefully more accurate predictions from the biological 
literature about the likely behavioural consequences of prenatal exposure to APM. 
3.5. Concluding Comments 
Despite the concern over the safety of APM, some of APM's protagonists believe 
that the number of complaints made about APM may stem from its high public profile 
as a synthetic sweetener (e.g., Moser, 1986, Kellen, 1987). They emphasize the 
benefits of APM to diabetic and overweight people and to all people who wish to 
avoid tooth decay. They note that food allergies are common to a range of foods and it 
may be unusual that so few problems are experienced with a food that is so widely 
consumed. However, only a handful of published studies have investigated the 
behavioural effects of APM, even though it is claimed to be the most thoroughly 
tested of all food additives, is currently used by over 100 million people and has been 
the target of over 4000 consumer complaints. The lack of published behavioural 
literature is a cause for concern, and this lack of literature impeded the adequate 
interpretation of the tentative findings of the present study; that prenatal exposure to 
even low doses of APM may affect RAM arm entry latencies even though the number of 
errors in the RAM may not be affected. Whether this finding is replicated and/ or of 
relevance to the safety of APM will only be established by further research of both 
the biological and behavioural effects of APM. 
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